Next Article in Journal
Synthesis, Spectroscopic Study and Radical Scavenging Activity of Kaempferol Derivatives: Enhanced Water Solubility and Antioxidant Activity
Next Article in Special Issue
Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells
Previous Article in Journal / Special Issue
Developmental Impairments in a Rat Model of Methyl Donor Deficiency: Effects of a Late Maternal Supplementation with Folic Acid
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications

Valeria Gasperi
Matteo Sibilano
Isabella Savini
Maria Valeria Catani
Department of Experimental Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133 Rome, Italy
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(4), 974;
Submission received: 30 January 2019 / Revised: 19 February 2019 / Accepted: 20 February 2019 / Published: 23 February 2019
(This article belongs to the Special Issue Functional Mechanism of B-Vitamins and Their Metabolites)


Niacin (also known as “vitamin B3” or “vitamin PP”) includes two vitamers (nicotinic acid and nicotinamide) giving rise to the coenzymatic forms nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). The two coenzymes are required for oxidative reactions crucial for energy production, but they are also substrates for enzymes involved in non-redox signaling pathways, thus regulating biological functions, including gene expression, cell cycle progression, DNA repair and cell death. In the central nervous system, vitamin B3 has long been recognized as a key mediator of neuronal development and survival. Here, we will overview available literature data on the neuroprotective role of niacin and its derivatives, especially focusing especially on its involvement in neurodegenerative diseases (Alzheimer’s, Parkinson’s, and Huntington’s diseases), as well as in other neuropathological conditions (ischemic and traumatic injuries, headache and psychiatric disorders).

1. Introduction

Niacin (also known as “vitamin B3” or “vitamin PP”) is the generic descriptor for two vitamers, nicotinic acid (pyridine-3-carboxylic acid) and nicotinamide (nicotinic acid amide), that give rise to the biologically active coenzymes, nicotinamide adenine dinucleotide (NAD) and its phosphate analog, the nicotinamide adenine dinucleotide phosphate (NADP) [1] (Figure 1). The two coenzymes take part in redox reactions crucial for energy production: in particular, the pyridinic ring can accept and donate a hydride ion (:H, the equivalent of a proton and two electrons), thus acting as an electron carrier. Nonetheless, NAD and NADP play different metabolic roles in the cytosol: the NADH/NAD+ ratio is small (about 8 × 10−4), thus favoring oxidative catabolism, whereas the NADPH/NADP+ ratio is higher (about 75), thus providing a strongly reducing environment for biosynthetic reactions [2,3].
Maintenance of the intracellular NAD pool is not only important to fuel redox metabolism, but also to support NAD-dependent, non-redox signaling pathways. NAD is indeed a substrate of ADP-ribosyltransferases that catalyze ADP-ribose transfer reactions, thus breaking down NAD to nicotinamide and ADP-ribosyl products, which play a key role in cellular signaling cascades regulating gene expression, cell cycle progression, insulin secretion, DNA repair, apoptosis and aging [4,5,6]. Finally, NAD has also been recognized as an endogenous agonist of purinergic P2Y1 and P2Y11 membrane subtype receptors, through which it inhibits neurotransmission in visceral smooth muscles [7] and activates immune cells [8,9], respectively.

2. Niacin Sources

Humans obtain niacin from both endogenous and exogenous sources. Only 2% of dietary tryptophan (Trp) is converted into niacin via a multistep pathway (see in next sections), occurring mainly in the liver [10]. Diet provides the vitamin as nicotinic acid, nicotinamide and Trp, as well as the active coenzymatic forms of niacin.

2.1. Exogenous Sources

Niacin is found in animal and vegetable foods. In meat and fish, the vitamin is present as NAD(P), whose amounts are higher in unprepared foods compared to processed foods (enzymatic hydrolysis of the coenzymes can occur during food preparation).
In mature cereal grains (particularly in corn), niacin is largely present as niacin-glycoside and, in a minor proportion, peptide-bound niacin, compounds collectively termed “niacinogens” [11]. When complexed in niacinogens, niacin is poorly available (only ~ 30%), as intestinal enzymes are not able to free niacin; nonetheless, alkali treatment of the grain increases niacin bioavailability [11].
Once ingested, free niacin can be adsorbed in the stomach, although the small intestine absorbs it faster. The mechanism of transport across the enterocyte brush border membrane is not fully clarified yet. Several transporters, indeed, appear to be involved in intestinal niacin uptake; among them, the most common are the human organic anion transporter-10 (hOAT-10, a proton-driven carrier that also mediates the transport of urate and p-aminohippurate) [12], responsible for niacin uptake at physiological concentrations [13], and the sodium-coupled monocarboxylate transporter (SMCT1 or SLC5A8, a transporter for lactate, pyruvate and short-chain fatty acids), specifically active at high pharmacological doses of nicotinic acid [14,15].
NAD and NADP are quickly hydrolyzed, by intestinal mucosa and liver glycohydrolases, to nicotinamide that is subsequently transported to tissues, where it is converted into coenzymatic forms as necessary. It seems noteworthy that nicotinamide moves freely into or out of the brain [16] and, as discussed in the next sections, such a property has important neurobiological implications.

2.2. Endogenous Synthesis

Starting from dietary Trp, niacin is synthesized via the kynurenine pathway (KP) (Figure 2), occurring mainly in the liver and, to a lesser extent, in extrahepatic tissues (especially upon immune cell activation) [17,18,19].
Tryptophan 2,3 dioxygenase (TDO), catalyzing the first reaction, is the rate-limiting enzyme. Several nutritional, hormonal and physio-pathological factors affect the efficiency of this anabolic pathway. Deficiencies of vitamin B6, riboflavin, iron and heme (all essential cofactors for specific enzymes), as well as of vitamin B1 and Trp itself, slow the reaction rate [18,20]. Overall: (i) a protein-enriched diet (particularly, consumption of foods with high concentrations of leucine, such as maize or sorghum) decreases niacin biosynthesis; (ii) unsaturated fatty acid-enriched diet increases it, while saturated fatty acids do not exert any effect; (iii) the transformation ratio is higher in diets containing starch with respect to sucrose-rich diets; (iv) caloric restriction drastically suppresses biosynthesis [18,21,22,23,24,25,26].
Among hormones, estrogens, glucorticoids and thyroxine are the best characterized modulators of the KP. Estrogens enhance TDO activity; enzyme activity is triplicated in women who are pregnant or are taking oral contraceptives [27,28]. Glucocorticoids stimulate de novo synthesis, by inducing TDO via a mechanism potentiated by glucagon and inhibited by insulin and adrenaline [18,29,30]. The effects of thyroxine on TDO activity are still controversial, as some studies suggested a positive action, while others did not observe any effect [31,32,33,34].
Due to individual differences, it has been estimated that, in human healthy individuals, Trp is converted to niacin with an average conversion efficiency of 60:1 [35]. Therefore, niacin intakes are expressed as niacin equivalents (NE; 1 mg NE = 1 mg niacin or 60 mg Trp): Recommended Dietary Allowance for adults is 16 mg NE/day for men and 14 mg NE/day for women, with a Tolerable Upper Intake Level of 35 mg/day, based on flushing as the critical adverse effect [36].

3. Vitamin Catabolism

The tight intracellular regulation of NAD is guaranteed not only at biosynthetic but also at catabolic level; in the latter case, NAD can be either recycled or metabolized and eliminated via urine (Figure 3) [37,38,39].
In the recycling pathways, NAD is metabolized to nicotinamide through the action of different ADP-ribosyltransferases. Sirtuins (SIRT) are NAD-dependent deacetylases and mono-ADP-ribosyl transferases belonging to the highly conserved family of silent information regulator-2 like proteins [40,41,42]. During deacetylation, NAD is hydrolyzed and the ε-acetyl lysine residues of the target protein is transferred onto the ADP-ribose moiety, thus forming O-acetyl-ADP ribose (Figure 3), which is a ligand of calcium channels in the plasma membrane [43]. SIRTs deacetylate a broad spectrum of proteins, thus modulating their activity, stability or localization. Depending on the targeted protein, these enzymes affect several biological processes, including transcription, cell cycle progression, genome stability, cell death and mitochondrial biogenesis [42,44,45]. ADP-ribosyltransferases (ARTC) and diphtheria toxin-like ADP-ribosyltransferases (ARTD) catalyze mono- and poly-ADP-ribosylation, respectively, of specific amino acids (arginine, cysteine, asparagine, histidine) of membrane proteins (Figure 3), thus regulating innate immunity and cell-to-cell cross-talk, as well as cell cycle, cell death and energy metabolism [46,47,48].
Finally, NAD(P) can be hydrolyzed to nicotinamide by two ADP-ribose cyclases, namely CD38 and CD157, which also release cyclic ADP-ribose, an endogenous activator of ryanodine receptor-mediated calcium release [49,50,51,52] and suggested to be involved in pathological diseases such as cancer, neurodegeneration and autoimmune diseases [53,54,55,56].
If not recycled, nicotinamide is methylated, by the cytosolic nicotinamide N-methyltransferase (NNMT) that uses S-adenosyl-methionine (SAM) as a methyl donor, and eliminated as oxidized metabolites (Figure 3). Altered enzyme activity has been linked to several pathological conditions, including neurodegenerative diseases, obesity, type 2 diabetes and cancer [57,58,59,60,61,62,63,64]. It should be recalled that, beside nicotinamide by-products, also those deriving from conjugation of nicotinic acid to glycine (nicotinuric acid) or from its methylation (1-methylnicotinic acid) can be found in urine [65,66,67].
Due to the multiplicity of NAD-dependent biological events, which lead to NAD degradation, cells need to replenish their intracellular NAD(P) pools; inhibition of NAD biosynthesis, for example, decreases intracellular NAD content within a few hours [68].

4. Severe Vitamin Deficiency

Severe niacin and/or Trp deficiency leads to a variety of clinical symptoms, including diarrhea, dermatitis and dementia, collectively known as “pellagra” or “the three D disease” [69]; although this disease has become rare in developed countries, it remains endemic in underdeveloped countries [70]. Pellagra is common in people who mostly eat maize [71], as well as in malnourished and alcoholic men [26]; other risk factors leading to vitamin B3 deficiency are nervous anorexia [72], AIDS [73], cancer [74] and chemotherapy [75], as well as malabsorptive disorders, such as Crohn’s disease [76].
Light sensitivity is high: dermatitis derives from deficits in poly(ADP-ribose) polymerase activity that leads to impaired DNA repair. Patients can show psychiatric symptoms (i.e., depression, paranoid behaviors, suicide and aggressive tendencies) that disappear when they take niacin [77,78]; some of these symptoms are also related to deficit of serotonin that derives from Trp [78].

5. Pharmacological Effects of Niacin

When supplemented at physiological amounts, nicotinic acid (15–20 mg/day) and nicotinammide (300 mg/day) are effective in treating traditional pellagra [77,78]; nonetheless, at higher concentrations, they display separate additional pharmacological activities, ranging from anti-dyslipidemic to anti-inflammatory action. The first evidence of lipid-altering effects of niacin dates back to 1955, when Altschul and co-workers reported the ability of 3000 mg/day nicotinic acid (but not nicotinamide) to reduce serum cholesterol in humans [79]. An every growing body of experimental data points to beneficial effects of nicotinic acid as an anti-hyperlipidemic agent. It is now well established that nicotinic acid efficaciously: (i) inhibits free fatty acid mobilization and lipolysis; (ii) reduces hepatic triglyceride synthesis and very low density lipoprotein (VLDL) secretion; (iii) inhibits VLDL conversion into low density lipoprotein (LDL); (iv) increases serum high-density-lipoprotein (HDL) levels; (v) triggers LDL conversion from small, dense particles to large, low density particles, (vi) reduces serum lipoprotein concentrations; and (vii) increases apolipoprotein A1 [80,81].
To date, the underlying mechanisms are still speculative; in particular, nicotinic acid (at levels higher than those achieved with diet) has been reported to bind to and activate GPR109A and GPR109B, two G0/Gi-coupled membrane receptors highly expressed in adipose tissue; nonetheless, these receptors are absent, or present only at low levels, in the liver [82]. Therefore, it is conceivable that nicotinic acid might exert its lowering-lipid effects through receptor-independent and -dependent mechanisms.
Due to the above mentioned positive effects, in 2008, nicotinic acid was commercially available as Trevaclyn®, Tredaptive® or Pelzont®, at the dose of 1.0 g (in combination with laropipram, an anti-flushing agent); this prescription product has been used to treat mixed dyslipidemic and/or primary hypercholesterolemic adults receiving statins [83]. However, results from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial [84], together with the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial [85,86], reported no clinical benefits (i.e., reduced risk of heart attack and stroke) from the long-lasting usage of niacin. A lack of efficacy, together with the onset of recurrent serious side effects (gastrointestinal, musculoskeletal, and skin-related), has led to drug withdrawal from the EU market.
In vitro and in vivo studies have also demonstrated that nicotinic acid (or activation of its molecular targets) exerts significant anti-inflammatory, anti-oxidant and anti-apoptotic activities in a variety of cells and tissues [87], thus being potentially beneficial for the management of several pathological conditions, including type-2 diabetes [88,89], obesity [90,91], atherosclerosis [92], kidney and lung injury [93,94,95], and hyperalgesia [96].
Also nicotinamide at high doses can exert specific pharmacological activities, particularly those related to cancer management. Indeed, several experimental and clinical studies have shown the ability of nicotinamide to sensitize tumors to radiation or chemotherapy [97,98,99,100]. Such an activity depends on activation of poly(ADP-ribose)-dependent apoptosis cascade, as well as on inhibition of myosin light chain kinase that, in turn, enhances microvascular flow, thus improving drug delivery and tumor oxygenation [97,98,99,100].

6. Niacin in the Central Nervous System

Besides dermatitis and diarrhea, niacin/tryptophan deficit symptoms also include several nervous system pathologies, such as dementia and depression, as well as other symptoms resembling those observed in neurodegenerative diseases. This evidence, together with accumulating in vitro and in vivo studies, has underlined the importance of niacin (particularly of nicotinamide) in growth and maintenance of the central nervous system (CNS) [101,102].
Nicotinamide biosynthesis actively occurs in the mammalian brain, which contains nanomolar-low micromolar concentrations of nicotinamide precursors derived from the KP [103,104,105]. Among them, quinolinic acid (unevenly present in different brain regions and, unlike nicotinamide, unable to cross the blood-brain barrier) displays evident neuroactivity [106]: it acts as a N-methyl-d-aspartate (NMDA) receptor agonist, thus causing excitotoxic neuronal lesions and oxidative stress [107]. In addition, quinolinic acid concentrations in the brain (particularly in the cortex) positively correlate with age, thus contributing to neuron synapsis dropout occurring during aging [108]. Finally, neuroinflammation, neurodegeneration and mood disturbs are accompanied by increased quinolinic acid levels in plasma and/or cerebrospinal fluid [10,109,110].
Among KP enzymes, TDO activity is rather low in a healthy human healthy brain [111], where it controls neurogenesis with implications in pre- and post-natal development, as well as in anxiety-related behavior [112]. TDO activity is enhanced under pathological conditions: high activity, indeed, has been found in neurodegenerative diseases and during tumor progression [113,114]. Also indolamine-pyrrole 2-3 dioxygenase (IDO) is expressed in the brain and its activity is increased upon pathological conditions, especially in depression, aging and neuroinflammatory diseases [115,116,117].
Like other vitamins (ascorbic acid, calcitriol and retinoic acid) [118,119,120,121,122], nicotinamide affects neurogenesis by accelerating differentiation of embryonic stem cells or neural progenitors into post-mitotic neurons [123,124]. In vitro vitamin supplementation promotes progression of undifferentiated stem cells to neural progenitors, which further mature into efficient GABAergic neurons; the pro-inducing action is time-dependent as the effects are more pronounced when the vitamin is early received early (day 0) [124]. Accordingly, decreased activity of NNMT (and, therefore, low levels of its metabolic product, N1-methylnicotinamide) is required for regulating pluripotency in stem cells: accumulation of NNMT’s substrates SAM and nicotinamide, indeed, promotes naïve to primed stem cell transition, by making SAM available for histone methylation and regulation of epigenetic events that control the metabolic changes occurring in early human development [125].
Beside the pro-differentiating action, nicotinamide also promotes neuronal survival, especially during oxidative stress conditions, and this effect is achieved via multiple mechanisms, including: (i) prevention of cytochrome c release and caspase 3- and 9-like activities, (ii) inhibition of caspase-3-mediated degradation of forkhead transcription factor (FOXO3a) and (iii) maintenance of protein kinase B (Akt)-dependent phosphorylation of FOXO3a [126].
CNS vascular integrity also positively correlates with NAD levels in brain, where a fine-tuned control of its metabolism occurs. As an example, heterozygous deletion of nicotinamide phosphoribosyltransferase (NAMPT) in the brain exacerbates focal ischemic stroke-induced neuronal death and brain damage [127], while its selective knock down in projection neurons of adult mice leads to motor dysfunction, neurodegeneration and death [128].
Finally, alterations of NAD metabolism are key features of Wallerian degeneration, a process occurring in crushed nerve fibers and leading to degeneration of the axon distal to the injury, representing an early event of age-related neurodegenerative disorders, as well as of chemotherapy-induced peripheral neuropathy [129]. By inducing intra-axonal Ca2+ increase through a pathway requiring the action of the pro-axon death protein SARM1, accumulation of nicotinamide mononucleotide is, indeed, responsible for loss of axonal integrity [130]. The pro-degenerative action of nicotinamide mononucleotide has also been documented during vincristine-induced degeneration in dorsal root ganglion axons [131]. Accordingly, increased activity of nicotinamide/nicotinic acid-mononucleotide-adenylyltransferase (NMNAT) 1–3 protects axons from degeneration, by either limiting nicotinamide mononucleotide levels or activating SIRT1 [132,133].

7. Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disease affecting about 30 million people worldwide, whose main hallmarks are the presence of amyloid β (Aβ) plaques and neurofibrillary tangles [134].
Even if tryptophan/niacin deficiency leads to neurological symptoms that cause neurodegenerative decline [135,136,137], a cause-effect relationship between niacin and AD pathogenesis has not been established (Table 1).
Dietary niacin may protect against AD and age-related cognitive decline, as suggested by a prospective population-based study: the Chicago Health and Aging Project (CHAP) study, considering a geographically defined community of 6158 residents aged 65 years and older, found an inverse association between AD and niacin intakes, after correction for several dietary (antioxidant nutrients, fats, folate, and vitamins B6, B12, B1 and B2) and non-dietary (age, education, race, ApoEε4) risk factors for dementia [135].
Although the existing epidemiologic evidence remains limited and inconclusive, niacin (especially nicotinamide) may be relevant for AD, especially keeping in mind that, by mediating key biological processes (such as energy metabolism, mitochondrial functions, calcium homeostasis, survival and cell death), NAD has lifespan-extending effects; this is particularly important in brain functions, including neurotransmission, learning and memory. NAD+ depletion and mitochondrial dysfunction, fundamental for synaptic plasticity, have usually been found in aging and AD onset [138,165]; accordingly, in mice models of AD, increasing NAD+ brain concentrations can restore mitochondrial function and antagonize cognitive decline [138,139]. Nicotinamide and/or nicotinamide mononucleotide also counteract amyloid toxicity, by reducing expression of AD-related genes (amyloid precursor protein and presenilin 1) and reactive oxygen species (ROS) generation, and by improving neuron survival: both in vitro (organotypic hippocampal slice cultures) and in vivo (AD model rats) studies have indeed underlined the protective effects of vitamin B3 against Aβ-induced neurotoxicity [140,141]. Moreover, the vitamin is able to lessen phosphorylated-Tau pathology in a novel AD mouse model with introduced DNA repair deficiency: nicotinamide riboside treatment significantly reduces DNA damage, neuroinflammation and cell death of hippocampal neurons, thus suggesting a therapeutic potential of NAD+ supplementation for AD [142]. Accordingly, the expression of Nmnat2, encoding for the enzyme catalyzing the conversion of nicotinamide to NAD+, is downregulated prior to neurodegeneration in a mouse model of dementia, and restoration of enzymatic activity has been shown to be neuroprotective against tauopathy [146]. Low levels of Nmnat2 have also been found in AD patients and its enzymatic activity is related to clearance of tau protein [147].
Lastly, fluctuations in NAD+ availability can reduce AD pathology, also by modulating SIRT1 activity and slowing aging and age-associated diseases [166,167]. Several studies have underlined the key role of SIRTs in AD prevention: in particular, deacetylase activity of SIRT1 has been shown to support the non-amyloidogenic pathway of AD [143], and to counteract phenomena, like neuroinflammation, oxidative stress and mitochondrial dysfunction, contributing to, and aggravating, AD [144,145].

8. Parkinson’s Disease

Parkinson’s disease (PD) is a progressive disorder characterized by degeneration of dopaminergic neurons within the substantia nigra, whose main hallmarks are abnormal aggregation of the α-synuclein protein, inhibition of mitochondrial respiratory complex 1, oxidative stress and neuroinflammation. Because only 5–10% of PD cases can be ascribed to genetic predisposition, several environmental factors may play a role in sporadic forms of PD [149]. Among them, vitamin B3 is a promising preventive and therapeutic factor (Table 1), as it can alleviate certain types of early-onset PD symptoms. NAD+ levels, indeed, fall in patients with PD and, conversely, increasing niacin intake can increase dopamine synthesis in the striatum and restore optimal NAD+/NADH ratio needed for the activity of mitochondrial complex 1 [148]. High niacin levels can also sequester transition metal ions (including iron) that usually accumulate together with the occurrence of aggregated misfolded proteins [149,150]. Furthermore, optimal levels of vitamin B3 are needed for reducing oxidative stress and neuroinflammation, also implicated in PD pathogenesis: low doses of niacin alter macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenothype, while exogenous NADPH suppresses oxidative stress and glia-mediated neuroinflammation [151,152].
Neurons are the only cells of the brain expressing NNMT that seems to play an important role in sustaining neuron homeostasis [153]. Despite numerous investigations, the exact cause-effect relationship between NNMT and PD neuropathogenesis remains unclear. Some authors refer to NNMT as a risk factor for PD, since its levels are elevated in the cerebrospinal fluid and midbrain dopamine neurons of PD patients [153,154]. High NNMT activity is associated with low activity of mitochondrial complex 1, thus providing a link with mitochondrial dysfunction triggering neurodegeneration [154,155]. It is noteworthy that N1-methylnicotinamide (the metabolite generated by the action of NNMT) is structurally similar to N-methy-l-4-phenylpyridinium (MPP+), a toxin damaging dopamine neurons [168]. Conversely, other studies have demonstrated that the enzyme is able to (i) counteract the MPP+-mediated toxicity on mitochondrial complex 1, (ii) activate neuronal autophagy for balancing energy sources and cell homeostasis, and (iii) modulate neuron morphology and differentiation, by inducing neurite branching, synaptophysin expression and dopamine accumulation and release [156]. Likewise, NAD supplementation or inactivation of NAD-consuming enzymes [like PARP-1, a poly(ADP-ribose) polymerase involved in DNA repair] rescue mitochondrial defects and protect neurons against degeneration, in familial forms of PD characterized by mutations in the pink1 gene; this finding suggests that neurotoxicity associated with mitochondrial defects may be prevented by modulating NAD+ salvage metabolism in order to enhance NAD availability [169].

9. Huntington’s Disease

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease characterized by typical progressive motor disturbances (involuntary movements of face and body, abnormalities in gait, posture and balance), psychiatric disorders (dementia) and other cognitive impairments [170]. HD is caused by a CAG expansion in the gene encoding for huntingtin (htt), located on chromosome 4; normally, the htt gene contains up to 35 CAG repeats, while in HD it has more than 36 CAG repeats that produce a mutant protein, with an abnormally long polyglutamine repeat (polyQ), responsible for the selective striatal degeneration of medium-sized spiny neurons and cerebral cortex [170]. In neurons, mutant htt protein aggregates, thus critically damaging cellular integrity by impairing proteostasis network, mitochondrial function and energy balance, transcriptional regulation, synaptic function and axonal transport [171].
From metabolomic studies, it has emerged that the metabolite (e.g., Trp, kynurenine, quinolinic acid and 3-hydroxykynurenine) content and activity of KP enzymes are pathologically altered in experimental HD models and human patients [109,110]. Moreover, in a Drosophila model of HD, disease progression has been found to be associated with a reduction in NAD levels, suggesting that dietetic or pharmacological supplementation of niacin (or its derivatives) may be useful in HD patients [157]. Several studies, indeed, have put forward a beneficial effect of vitamin B3 in HD (Table 1): for example, nicotinamide is protective against toxicity of polyQ proteins in Drosophila HD models [158], while, in transgenic mouse models, it restores brain-derived neurotrophic factor (BDNF) protein levels, increases acetylated peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), a master regulator of mitochondrial biogenesis, and improves motor deficits [159]. Nicotinamide effects do not depend on inhibition of mutant htt aggregation, but rather on replenishment of NAD levels required to restore energy balance dysregulation occurring in HD.
Further insights into the neuroprotective action of nicotinamide derive from a recent study showing how nicotinamide dose-dependently prevents motor abnormality in 3˗nitropropionic acid-induced rat model of HD. Such an effect seems to be linked to prevention of oxidative stress (i.e., decrease in malondialdehyde and nitrites, increase in glutathione), as well as to inhibition of neuronal death in the striatum, most likely through a PARP-1-dependent mechanism [160]. Accordingly, PARP-1 is activated in response to 3- nitropropionic acid-induced neurotoxicity [161] and PARP-1-triggered astrocyte death is prevented by nicotinamide [162]. Like PARP-1, SIRTs are involved in HD neurodegeneration. In particular, SIRT1 is impaired, most likely because of the ability of mutant htt to directly bind and inhibit it; subsequent hyperacetylation and inactivation of specific genes lead to abrogation of the deacetylase pro-survival action [172]. Accordingly, increased SIRT1 activity rescues neurons from mutant htt toxicity and ameliorates pathological mechanisms underlying HD onset [163,164].
All these findings are somewhat controversial, since other studies reported opposite effects. By using the YAC128 transgenic model (expressing the full-length human mutant htt gene), Naia and co-workers [173] compared the effects of nicotinamide (a SIRT1 inhibitor) and resveratrol (a SIRT1 activator), both in vitro and in vivo. Both compounds were able to modify histone H3 acetylation and counteract mitochondrial dysfunction in striatal and cortical neurons isolated from YAC128 embryos; nonetheless, only resveratrol ameliorated energy homeostasis and mitochondrial function, as well as motor coordination, in in vivo HD models. Counterintuitively, in vivo nicotinamide supplementation (especially at high concentrations) did not cause any improvement in motor behavior and, furthermore, it worsened motor performance in wild-type control mice. The harmful action has further been documented in other neurodegenerative pathologies: in lactacystin-lesioned rats (an in vivo model of PD), one-month nicotinamide supplementation leads to SIRT1 inhibition and over-expression of neurotrophic and anti-apoptotic factors, nonetheless it exacerbated degeneration of dopaminergic neurons [174].
Therefore, these data underscore the need of full understanding the pathogenetic mechanisms of neurodegeneration, before suggesting any therapeutic challenge to slow down the progression of symptoms.

10. Other Neurological Diseases

Besides neurodegeneration, the impact of vitamin B3 on CNS has also been investigated in other neuropathological conditions, among which (i) ischemic and traumatic injuries, (ii) headache and (iii) psychiatric disorders (Table 2).

10.1. Ischemic and Traumatic Injuries

When brain cells are deprived of oxygen for more than a few seconds, severe damage occurs, culminating in cell death, through cerebral infarction or ischemic stroke. During reperfusion following a transient ischemic episode, other significant harm (including oxidative stress, leukocyte infiltration, mitochondrial dysfunction, platelet activation and aggregation, complement activation, and blood-brain-barrier disruption) also occur, contributing to neurological dysfunction [200].
Re-oxygenation of neural tissue dramatically impairs NAD+/NADH recycling, an event known as NADH hyperoxidation [201]. Over the years, the potential neuroprotective and neurorestorative role of vitamin B3 in ischemic brain injury has extensively been demonstrated in in vitro and in vivo models. By using hippocampal slices, Shetty and co-workers [183] demonstrated that NADH hyperoxidation is correlated with diminished neuronal recovery that can be rescued by enhancing NAD+ levels. Pre-treatment of brain tissue with nicotinamide (to enhance NAD+ availability) or PARP-1 antagonists (to lessen NAD+ consumption), indeed, prevents mitochondrial dysfunction, improves ATP content and stimulates neuronal recovery, during re-oxygenation [183]. Nicotinamide seems to be efficacious also when provided after ischemia-reperfusion injury. For example, rats receiving a single high dose or repeated low doses of vitamin B3 after cardiac arrest show reduced neurologic deficits, hippocampal apoptosis, axonal injury and microglial activation in corpus callosum [181]. Nicotinamide-dependent mechanisms underlying these effects include restoration of NAD(P) content and decrease in oxidative stress, along with repression of mitogen-activated protein kinase signaling and caspase 3 cleavage in brain tissue [181]. These data are in agreement with previous reports showing how nicotinamide significantly reduces brain infarct size and improves neurological deficits in different rat strains [202,203,204,205,206]. Interestingly, neurorestoring effects are also present when niacin is provided several hours after ischemic damage: when administrated 24 h after a middle cerebral artery occlusion, Niaspan (a FDA-approved prolonged release formulation of niacin) increases local cerebral blood flow, promotes angiogenesis (via angiopoietin1/Tie2, Akt and endothelial NOS pathways) and arteriogenesis (via tumor necrosis factor-alpha-converting enzyme and Notch signaling), and ameliorates functional deficits [184,185].
NAMPT is critically involved in vitamin B3 effects. Proof of its key role include: (i) decreased NAMPT activity significantly worsens post-ischemic brain damage [189,190]; (ii) heterozygous Nampt deletion aggravates brain damage following photothrombosis-induced focal ischemia [190], (iii) Nampt over-expression reduces infarct size [191]. Accordingly, when intraventricularly injected, the NAMPT substrate nicotinamide mononucleotide reverts the detrimental effects of FK866 (a NAMPT inhibitor) [189], ameliorates hippocampal injury and improves neurological outcome, by decreasing poly-ADP-ribosylated proteins and NAD+ catabolism [182].
The evidence of niacin efficacy against ischemic insult strongly prompted researchers to investigate its validity in other brain injuries, including traumatic brain injury (TBI). Rats receiving niacin following a cortical contusion injury (an experimental model of TBI) show reduced behavioral deficits and improved long-lasting functional recovery [175,176,177,178,179,180].
Regardless the type of brain injury, greater beneficial effects have been observed when vitamin B3 was administrated in combination with other “natural compounds”. Co-administration of nicotinamide and progesterone not only increases function recovery, reduces lesion cavitation and tissue loss in both injured cortex and reactive astrocytes, but also modulates expression of genes involved in inflammatory and immune responses, including Ccr1 (chemokine (C-C motif) receptor 1), Clec4e (C-type lectin domain family 4, member 3), Fn1 (fibronectin 1), Hmox1 (heme-oxygenase 1), Hspb1 (heat shock protein b1), Igf1 and 2 (insulin like growth factor 1 and 2), Il1β (interleukin 1 β), Il16 and 18 (interleukin 16 and 18), Mmp8 and 9 (matrix metallopeptidase 8 and 9), Niacr1 (niacin receptor 1) and Ptgs2 (prostaglandin-endoperoxide synthase 2) [187,188]. In an in vitro model of ischemia-reperfusion injury, combination of niacin and selenium (at clinically relevant doses) synergistically attenuates cortical cell injury, by increasing Akt phosphorylation and expression of nuclear factor erythroid 2-related factor 2, stimulating glutathione redox cycle and reducing hydrogen peroxide levels [186].

10.2. Headache

Affecting more than fifty percent of adult population, headache represents one of the most widespread causes of disability worldwide. Pathogenic mechanisms underlying migraine and tension-type headache (the most common primary headache types) are mostly superimposable: headache, indeed, is triggered by trigeminovascular complex activation that leads to intracranial vessel vasoconstriction followed by extracranial vessel vasodilation and perivascular nociceptive nerve activation. Pressure changes in cerebrospinal fluid and/or intracranial veins are also involved [207,208].
Some nutrients, such as magnesium, carnitine, coenzyme Q10, vitamins (B2, B12, D) and alpha lipoic acid, can be used as preventive compounds able to counteract headache migraine attacks [209]. When orally, intramuscularly or intravenously administrated, vitamin B3 (especially, nicotinic acid) has therapeutic effects in headache management [210,211,212,213,214,215]. It has been proposed that niacin might exert beneficial effects by acting at both central and peripheral levels; in particular, it efficaciously dilates intracranial vessels and subsequently contracts extracranial vessels, favoring, in parallel, the release of compounds leading to peripheral vasodilation and cutaneous flushing. Taking into account that plasma content of serotonin inversely correlates with headache onset, niacin acts, at the central level, by increasing Trp-dependent synthesis of serotonin, via feedback inhibition of the KP [194]. At the peripheral level, pharmacological doses of nicotinic acid increase skin biosynthesis of prostaglandin D2 [195] and the plasma content of its by-product 9a,11b-PGF2, in healthy volunteers [196].
It should also be mentioned that alterations of mitochondrial regulatory networks play a key role in migraine pathophysiology [192,193]. Therefore, by enhancing substrate availability for complex I and reducing lactate concentration, niacin might restore mitochondrial energy metabolism and ameliorate blood flow and oxygenation in sore skeletal muscle, especially in tension-type headache.

10.3. Psychiatric Disorders

A large number of mental disorders have been shown to be influenced by dietary habits, leading to the development of nutritional guidelines for prevention and/or treatment of psychological disorders, including depression, anxiety, schizophrenia, bipolar disorders and psychological distress. In particular, vitamin B3 dysmetabolism may be linked with some of these neuropsychiatric disorders, although the literature reports conflicting data: as an example, an epidemiologic study conducted on 140 subjects (73 controls and 67 patients with schizophrenia) has revealed that affected individuals show significantly lower dietary intakes of specific nutrients, including niacin [197], whereas a 1-year case-control study performed on 101 controls and 128 cases of schizophrenia found a direct relationship between the disease and nicotinamide levels [198].
The main etiological factors involved in mood disorders appear to be metabolites produced in the KP, as a consequence of the shunt of Trp from serotonin synthesis to kynurenine formation [216]. Serotonergic neurotransmission, indeed, is compromised in the brain of depressed individuals, as a result of activated KP. Since IDO activity is induced under inflammatory and oxidative conditions, and KP is mostly active in astrocytes and microglia (also responsible for production of pro-inflammatory mediators), it has been proposed that unbalanced KP leads to impaired glial-neuronal network, thus priming the CNS against psychological stress [217]. In human postmortem studies, high levels of kynurenic acid (deriving from transamination of kynurenine instead of hydroxylation, see Figure 2) have been found in the prefrontal cortex of schizophrenic individuals; this finding may have clinical relevance, as kynurenic acid is an antagonist of both NMDA and nicotinic acetylcholine receptors, whose blockade is involved in cognitive deficits associated with the disease [218]. Like schizophrenia, alterations in kynurenine precursor have also been observed in bipolar disorder, although, in this case, nicotinamide levels represent a better prognostic factor; indeed, higher nicotinamide levels are correlated with suicide as a cause of death in bipolar patients (1.3-fold increase with respect to bipolar individuals who died from other causes) [219].
The immune-related imbalance of KP can also be responsible for dendritic atrophy and anhedonia associated with major depressive disorder (MDD): comparison between controls (20 healthy subjects) and patients (29 unmedicated individuals who met the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for MDD) revealed, in the MDD group, a lower neuroprotective index [ratio between kynurenic acid (neuroprotective) and quinolinic acid (neurotoxic)], which was negatively correlated with anhedonia and positively correlated with hippocampal and amygdala volume [220]. According to these data, tdo knock-out mice show, if compared to wild-type littermates, higher levels of Trp and serotonin in the hippocampus and midbrain, which are connected to increased neurogenesis and amelioration of anxiety-related behavior [221].
Together, such findings suggest a potential antidepressant effect of vitamin B3 or its related products. In a patient with bipolar type II disorder, nicotinamide supplementation (1 g three times daily) for over 11 years has proven effective in maintaining the patient stable and calm [199]. Although a single case report is weak and does not allow us to generalize the results, it may aid in the understanding the potential additional mechanisms accounting for mental disorders.

11. Conclusions

A growing body of evidence highlights the key role of vitamin B3 in neuronal health. What is emerging is that niacin bioavailability is crucial for neuronsurvival and functions: indeed, vitamin deficiency has been recognized as a pathogenic factor for neurological deficits and dementia, as well as for neuronal injury and psychiatric disorders.
Several molecular mechanisms are influenced by vitamin B3 (Figure 4), often strictly linked each other, thus making it difficult to define the precise mechanisms of action of this dietary metabolite. Although further research is needed, it may be speculated that optimal dietary intake of the vitamin will support neuronal health and delay neurodegeneration.


This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.


ADAlzheimer’s disease
Aktprotein kinase B
ARTDdiphtheria toxin-like ADP-ribosyltransferases
CNScentral nervous system
FOXO3aforkhead transcription factor
HDHuntington’s disease
HDLhigh density lipoprotein
hOAT-10human organic anion transporter-10
IDOindolamine-pyrrole 2-3 dioxygenase
KPkynurenine pathway
LDLlow density lipoprotein
MDDmajor depressive disorder
NAD(P)nicotinamide adenine dinucleotide (phosphate)
NAMPTnicotinamide phosphoribosyltransferase
NEniacin equivalents
PARPpoly(ADP-ribose) polymerase
PDParkinson’s disease
polyQpolyglutamine repeat
ROSreactive oxygen species
SMCT1/SLC5A8sodium-coupled monocarboxylate transporter
TBItraumatic brain injury
TDOtryptophan 2,3 dioxygenase
VLDLvery low density lipoprotein


  1. Spies, T.D.; Bean, W.B.; Stone, R.E. The Treatment of Subclinical and Classic Pellagra Use of Nicotinic Acid, Nicotinic Acid Amide and Sodium Nicotinate, with Special Reference to the Vasodilator Action and the Effect on Mental Symptoms. JAMA 1938, 111, 584–592. [Google Scholar] [CrossRef]
  2. Magni, G.; Amici, A.; Emanuelli, M.; Orsomando, G.; Raffaelli, N.; Ruggieri, S. Enzymology of NAD+ Homeostasis in Man. Cell. Mol. Life Sci. 2004, 61, 19–34. [Google Scholar] [CrossRef] [PubMed]
  3. Goodman, R.P.; Calvo, S.E.; Mootha, V.K. Spatiotemporal Compartmentalization of Hepatic NADH and NADPH Metabolism. J. Biol. Chem. 2018, 293, 7508–7516. [Google Scholar] [CrossRef] [PubMed]
  4. Kirkland, J.B. Niacin Status, NAD Distribution and ADP-Ribose Metabolism. Curr. Pharm. Des. 2009, 15, 3–11. [Google Scholar] [CrossRef] [PubMed]
  5. Nikiforov, A.; Kulikova, V.; Ziegler, M. The Human NAD Metabolome: Functions, Metabolism and Compartmentalization. Crit. Rev. Biochem. Mol. Biol. 2015, 50, 284–297. [Google Scholar] [CrossRef] [PubMed]
  6. Anderson, K.A.; Madsen, A.S.; Olsen, C.A.; Hirschey, M.D. Metabolic Control by Sirtuins and Other Enzymes that Sense NAD(+), NADH, or Their Ratio. Biochim. Biophys. Acta Bioenerg. 2017, 1858, 991–998. [Google Scholar] [CrossRef] [PubMed]
  7. Mutafova-Yambolieva, V.N.; Hwang, S.J.; Hao, X.; Chen, H.; Zhu, M.X.; Wood, J.D.; Ward, S.M.; Sanders, K.M. Beta-Nicotinamide Adenine Dinucleotide is an Inhibitory Neurotransmitter in Visceral Smooth Muscle. Proc. Natl. Acad. Sci. USA 2007, 104, 16359–16364. [Google Scholar] [CrossRef] [PubMed]
  8. Moreschi, I.; Bruzzone, S.; Nicholas, R.A.; Fruscione, F.; Sturla, L.; Benvenuto, F.; Usai, C.; Meis, S.; Kassack, M.U.; Zocchi, E.; De Flora, A. Extracellular NAD+ Is an Agonist of the Human P2Y11 Purinergic Receptor in Human Granulocytes. J. Biol. Chem. 2008, 281, 31419–31429. [Google Scholar] [CrossRef] [PubMed]
  9. Klein, C.; Grahnert, A.; Abdelrahman, A.; Muller, C.E.; Hauschildt, S. Extracellular NAD(+) Induces a Rise in [Ca(2+)](i) in Activated Human Monocytes via Engagement of P2Y(1) and P2Y(11) Receptors. Cell Calcium 2009, 46, 263–272. [Google Scholar] [CrossRef] [PubMed]
  10. Schwarcz, R.; Stone, T.W. The Kynurenine Pathway and the Brain: Challenges, Controversies and Promises. Neuropharmacology 2016, 112, 237–247. [Google Scholar] [CrossRef] [PubMed]
  11. Prousky, J.; Millman, C.; Kirkland, J. Pharmacologic Use of Niacin. J. Evid.-Based Complement. Altern. Med. 2011, 16, 91–101. [Google Scholar] [CrossRef]
  12. Bahn, A.; Hagos, Y.; Reuter, S.; Balen, D.; Brzica, H.; Krick, W.; Burckhardt, B.C.; Sabolic, I.; Burckhardt, G. Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13). J. Biol. Chem. 2008, 283, 16332–16341. [Google Scholar] [CrossRef] [PubMed]
  13. Kumar, J.S.; Subramanian, V.S.; Kapadia, R.; Kashyap, M.L.; Said, H.M. Mammalian Colonocytes Possess a Carrier-Mediated Mechanism for Uptake of Vitamin B3 (niacin): Studies Utilizing Human and Mouse Colonic Preparations. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, 207–213. [Google Scholar] [CrossRef] [PubMed]
  14. Gopal, E.; Miyauchi, S.; Martin, P.M.; Ananth, S.; Roon, P.; Smith, S.B.; Ganapathy, V. Transport of Nicotinate and Structurally Related Compounds by Human SMCT1 (SLC5A8) and Its Relevance to Drug Transport in the Mammalian Intestinal Tract. Pharm. Res. 2007, 24, 575–584. [Google Scholar] [CrossRef] [PubMed]
  15. Gopal, E.; Fei, Y.J.; Miyauchi, S.; Zhuang, L.; Prasad, P.D.; Ganapathy, V. Sodium-Coupled and Electrogenic Transport of B-Complex Vitamin Nicotinic Acid by slc5a8, a Member of the Na/glucose Co-transporter Gene Family. Biochem. J. 2005, 388, 309–316. [Google Scholar] [CrossRef] [PubMed]
  16. Spector, R. Niacinamide Transport Through the Blood-Brain Barrier. Neurochem. Res. 1987, 12, 27–31. [Google Scholar] [CrossRef] [PubMed]
  17. Badawy, A.A. Tryptophan Metabolism in Alcoholism. Nutr. Res. Rev. 2002, 15, 123–152. [Google Scholar] [CrossRef] [PubMed]
  18. Badawy, A.A. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int. J. Tryptophan Res. 2017, 10. [Google Scholar] [CrossRef] [PubMed]
  19. Müller, F. Flavin-Dependent Hydroxylases. Biochem. Soc. Trans. 1985, 13, 443–447. [Google Scholar] [CrossRef] [PubMed]
  20. Shibata, K.; Kobayashi, R.; Fukuwatari, T. Vitamin B1 Deficiency Inhibits the Increased Conversion of Tryptophan to Nicotinamide in Severe Food-Restricted Rats. Biosci. Biotechnol. Biochem. 2015, 79, 103–108. [Google Scholar] [CrossRef] [PubMed]
  21. Shibata, K.; Onodera, M. Comparison of Tryptophan-Niacin Conversion in Rats Fed with a Nicotinic Acid-Free Diet Containing Egg White, Egg White Proteolysate, or Mixtures of Amino Acids. Agric. Biol. Chem. 1991, 55, 1291–1298. [Google Scholar] [CrossRef]
  22. Shibata, K.; Nomamoto, R.; Iwai, K. Effect of Dietary Protein levels on the Urinary Excretion of Nicotinamide and Its Metabolites in Rats. Agric. Biol. Chem. 1988, 53, 1765–1769. [Google Scholar] [CrossRef]
  23. Shibata, K. Nutritional Factors that Regulate on the Conversion of L-Tryptophan to Niacin. Adv. Exp. Med. Biol. 1999, 467, 711–716. [Google Scholar] [CrossRef] [PubMed]
  24. Shibata, K. Organ Co-Relationship in Tryptophan Metabolism and Factors That Govern the Biosynthesis of Nicotinamide from Tryptophan. J. Nutr. Sci. Vitaminol. 2018, 64, 90–98. [Google Scholar] [CrossRef] [PubMed]
  25. Shibata, K.; Nakata, C.; Fukuwatari, T. Moderate Food Restriction Suppresses the Conversion of L-tryptophan to Nicotinamide in Weaning Rats. Biosci. Biotechnol. Biochem. 2014, 78, 478–481. [Google Scholar] [CrossRef] [PubMed]
  26. Badawy, A.A. Pellagra and Alcoholism: A Biochemical Perspective. Alcohol Alcohol. 2014, 49, 238–250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Bender, D.A. Inhibition in Vitro of the Enzymes of the Oxidative Pathway of Tryptophan Metabolism and of Nicotinamide Nucleotide Synthesis by Benserazide, Carbidopa and Isoniazid. Biochem. Pharmacol. 1980, 29, 707–712. [Google Scholar] [CrossRef]
  28. Braidman, I.P.; Rose, D.P. The Effect of Sex Hormones on the Activity of Tryptophan Oxygenase and Other Corticosteroid-Inducible Enzymes in Rat Liver. Biochem. J. 1971, 122, 28P. [Google Scholar] [CrossRef] [PubMed]
  29. Nakamura, T.; Shinno, H.; Ichihara, A. Insulin and Glucagon as a New Regulator System for Tryptophan Oxygenase Activity Demonstrated in Primary Cultured Rat Hepatocytes. J. Biol. Chem. 1980, 255, 7533–7535. [Google Scholar] [PubMed]
  30. Nakamura, T.; Niimi, S.; Nawa, K.; Noda, C.; Ichihara, A.; Takagi, Y.; Anai, M.; Sakaki, Y. Multihormonal Regulation of Transcription of the Tryptophan 2,3-Dioxygenase Gene in Primary Cultures of Adult Rat Hepatocytes with Special Reference to the Presence of a Transcriptional Protein Mediating the Action of Glucocorticoids. J. Biol. Chem. 1987, 262, 723–732. [Google Scholar]
  31. Labrie, F.; Korner, A. Effect of Glucagon, Insulin, and Thyroxine on Tyrosine Transaminase and Tryptophan Pyrrolase of Rat Liver. Arch. Biochem. Biophys. 1969, 129, 75–78. [Google Scholar] [CrossRef]
  32. Chiancone, F.M. Enzyme Activities in the Tryptophan → Nicotinic Acid Path in Physiopathology. Ital. J. Biochem. 1964, 13, 1–30. [Google Scholar]
  33. Ku, Y.; Rogers, Q.R.; Harper, A.E. Effects of Thyroxine and Cortisol on Liver Threonine Dehydratase and Tryptophan Pyrrolase in Rats Fed a High Protein Diet. Proc. Soc. Exp. Biol. Med. 1969, 130, 556–563. [Google Scholar] [CrossRef] [PubMed]
  34. Shibata, K.; Toda, S. Effect of Thyroxine on the Metabolism of Tryptophan to Nicotinamide in Rats. Biosci. Biotechnol. Biochem. 1994, 58, 1757–1762. [Google Scholar] [CrossRef]
  35. Horwitt, M.K.; Harper, A.E.; Henderson, L.M. Niacin-Tryptophan Relationships for Evaluating Niacin Equivalents. Am. J. Clin. Nutr. 1981, 34, 423–427. [Google Scholar] [CrossRef] [PubMed]
  36. Food and Nutrition Board. Dietary Reference Intakes for Thiamine, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Panthotenic Acid, Biotin and Choline; National Academy Press: Washington, DC, USA, 1998; pp. 374–389. [Google Scholar]
  37. Long, A.; Klimova, N.; Kristian, T. Mitochondrial NUDIX hydrolases: A Metabolic Link Between NAD Catabolism, GTP and Mitochondrial Dynamics. Neurochem. Int. 2017, 109, 193–201. [Google Scholar] [CrossRef] [PubMed]
  38. Bogan, K.L.; Evans, C.; Belenky, P.; Song, P.; Burant, C.F.; Kennedy, R.; Brenner, C. Identification of Isn1 and Sdt1 as Glucose- and Vitamin-Regulated Nicotinamide Mononucleotide and Nicotinic Acid Mononucleotide [corrected] 5′-Nucleotidases Responsible for Production of Nicotinamide Riboside and Nicotinic Acid Riboside. J. Biol. Chem. 2009, 284, 34861–34869. [Google Scholar] [CrossRef]
  39. Wielgus-Kutrowska, B.; Kulikowska, E.; Wierzchowski, J.; Bzowska, A.; Shugar, D. Nicotinamide Riboside, an Unusual, Non-Typical, Substrate of Purified Purine-Nucleoside Phosphorylases. Eur. J. Biochem. 1997, 243, 408–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Haigis, M.C.; Mostoslavsky, R.; Haigis, K.M.; Fahie, K.; Christodoulou, D.C.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Karow, M.; Blander, G.; et al. SIRT4 Inhibits Glutamate Dehydrogenase and Opposes the Effects of Calorie Restriction in Pancreatic Beta Cells. Cell 2006, 126, 941–954. [Google Scholar] [CrossRef] [PubMed]
  41. Mao, Z.; Hine, C.; Tian, X.; Van Meter, M.; Au, M.; Vaidya, A.; Seluanov, A.; Gorbunova, V. SIRT6 Promotes DNA Repair Under Stress by Activating PARP1. Science 2011, 332, 1443–1446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Wang, Y.; He, J.; Liao, M.; Hu, M.; Li, W.; Ouyang, H.; Wang, X.; Ye, T.; Zhang, Y.; Ouyang, L. An Overview of Sirtuins as Potential Therapeutic Target: Structure, Function and Modulators. Eur. J. Med. Chem. 2019, 161, 48–77. [Google Scholar] [CrossRef] [PubMed]
  43. Imai, S.; Guarente, L. Ten Years of NAD-Dependent SIR2 Family Deacetylases: Implications for Metabolic Diseases. Trends Pharmacol. Sci. 2010, 31, 212–220. [Google Scholar] [CrossRef] [PubMed]
  44. Singh, C.K.; Chhabra, G.; Ndiaye, M.A.; Garcia-Peterson, L.M.; Mack, N.J.; Ahmad, N. The Role of Sirtuins in Antioxidant and Redox Signaling. Antioxid. Redox Signal. 2018, 28, 643–661. [Google Scholar] [CrossRef] [PubMed]
  45. Xu, J.; Jackson, C.W.; Khoury, N.; Escobar, I.; Perez-Pinzon, M.A. Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection. Front. Endocrinol. 2018, 9, 702. [Google Scholar] [CrossRef] [PubMed]
  46. Cohen, M.S.; Chang, P. Insights Into the Biogenesis, Function, and Regulation of ADP-Ribosylation. Nat. Chem. Biol. 2018, 14, 236–243. [Google Scholar] [CrossRef] [PubMed]
  47. Kunze, F.A.; Hottiger, M.O. Regulating Immunity via ADP-Ribosylation: Therapeutic Implications and Beyond. Trends Immunol. 2019. [Google Scholar] [CrossRef] [PubMed]
  48. Crawford, K.; Bonfiglio, J.J.; Mikoč, A.; Matic, I.; Ahel, I. Specificity of Reversible ADP-Ribosylation and Regulation of Cellular Processes. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 64–82. [Google Scholar] [CrossRef] [PubMed]
  49. Lee, H.C.; Walseth, T.F.; Bratt, G.T.; Hayes, R.N.; Clapper, D.L. Structural Determination of a Cyclic Metabolite of NAD+ with Intracellular Ca2+-Mobilizing Activity. J. Biol. Chem. 1989, 264, 1608–1615. [Google Scholar] [PubMed]
  50. Swarbrick, J.M.; Graeff, R.; Garnham, C.; Thomas, M.P.; Galione, A.; Potter, B.V. ‘Click Cyclic ADP-Ribose’: A Neutral Second Messenger Mimic. Chem. Commun. 2014, 50, 2458–2461. [Google Scholar] [CrossRef] [PubMed]
  51. Ferrero, E.; Lo Buono, N.; Horenstein, A.L.; Funaro, A.; Malavasi, F. The ADP-Ribosyl Cyclases--the Current Evolutionary State of the ARCs. Front. Biosci. 2014, 19, 986–1002. [Google Scholar] [CrossRef]
  52. Wei, W.; Graeff, R.; Yue, J. Roles and Mechanisms of the CD38/Cyclic Adenosine Diphosphate Ribose/Ca(2+) Signaling Pathway. World J. Biol. Chem. 2014, 5, 58–67. [Google Scholar] [CrossRef] [PubMed]
  53. Pehar, M.; Harlan, B.A.; Killoy, K.M.; Vargas, M.R. Nicotinamide Adenine Dinucleotide Metabolism and Neurodegeneration. Antioxid. Redox Signal. 2018, 28, 1652–1668. [Google Scholar] [CrossRef] [PubMed]
  54. Chmielewski, J.P.; Bowlby, S.C.; Wheeler, F.B.; Shi, L.; Sui, G.; Davis, A.L.; Howard, T.D.; D’Agostino, R.B., Jr.; Miller, L.D.; Sirintrapun, S.J.; et al. CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD(+) Pools. Mol. Cancer Res. 2018, 11, 1687–1700. [Google Scholar] [CrossRef] [PubMed]
  55. Morandi, F.; Horenstein, A.L.; Rizzo, R.; Malavasi, F. The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators Inflamm. 2018, 2018, 7019398. [Google Scholar] [CrossRef] [PubMed]
  56. Zhang, M.; Ying, W. NAD(+) Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications. Antioxid. Redox Signal. 2018, 30, 890–905. [Google Scholar] [CrossRef] [PubMed]
  57. Komatsu, M.; Kanda, T.; Urai, H.; Kurokochi, A.; Kitahama, R.; Shigaki, S.; Ono, T.; Yukioka, H.; Hasegawa, K.; Tokuyama, H.; et al. NNMT Activation Can Contribute to the Development of Fatty Liver Disease by Modulating the NAD (+) Metabolism. Sci. Rep. 2018, 8, 8637. [Google Scholar] [CrossRef] [PubMed]
  58. Bach, D.H.; Kim, D.; Bae, S.Y.; Kim, W.K.; Hong, J.Y.; Lee, H.J.; Rajasekaran, N.; Kwon, S.; Fan, Y.; Luu, T.T.; et al. Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. Mol. Ther. Nucleic Acids 2018, 11, 455–467. [Google Scholar] [CrossRef] [PubMed]
  59. Crujeiras, A.B.; Pissios, P.; Moreno-Navarrete, J.M.; Diaz-Lagares, A.; Sandoval, J.; Gomez, A.; Ricart, W.; Esteller, M.; Casanueva, F.F.; Fernandez-Real, J.M. An Epigenetic Signature in Adipose Tissue Is Linked to Nicotinamide N-Methyltransferase Gene Expression. Mol. Nutr. Food Res. 2018, 62, e1700933. [Google Scholar] [CrossRef] [PubMed]
  60. Kannt, A.; Rajagopal, S.; Kadnur, S.V.; Suresh, J.; Bhamidipati, R.K.; Swaminathan, S.; Hallur, M.S.; Kristam, R.; Elvert, R.; Czech, J.; et al. A Small Molecule Inhibitor of Nicotinamide N-Methyltransferase for the Treatment of Metabolic Disorders. Sci. Rep. 2018, 8, 3660. [Google Scholar] [CrossRef] [PubMed]
  61. Rudolphi, B.; Zapp, B.; Kraus, N.A.; Ehebauer, F.; Kraus, B.J.; Kraus, D. Body Weight Predicts Nicotinamide N-Methyltransferase Activity in Mouse Fat. Endocr. Res. 2018, 43, 55–63. [Google Scholar] [CrossRef] [PubMed]
  62. Nejabati, H.R.; Mihanfar, A.; Pezeshkian, M.; Fattahi, A.; Latifi, Z.; Safaie, N.; Valiloo, M.; Jodati, A.R.; Nouri, M. N1-Methylnicotinamide (MNAM) as a Guardian of Cardiovascular System. J. Cell. Physiol. 2018, 233, 6386–6394. [Google Scholar] [CrossRef] [PubMed]
  63. Schmeisser, K.; Parker, J.A. Nicotinamide-N-Methyltransferase Controls Behavior, Neurodegeneration and Lifespan by Regulating Neuronal Autophagy. PLoS Genet. 2018, 14, e1007561. [Google Scholar] [CrossRef] [PubMed]
  64. Lu, X.M.; Long, H. Nicotinamide N-Methyltransferase as a Potential Marker for Cancer. Neoplasma 2018, 65, 656–663. [Google Scholar] [CrossRef] [PubMed]
  65. Kremer, J.I.; Gömpel, K.; Bakuradze, T.; Eisenbrand, G.; Richling, E. Urinary Excretion of Niacin Metabolites in Humans After Coffee Consumption. Mol. Nutr. Food Res. 2018, 62, 1700735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Liu, M.; Zhang, D.; Wang, X.; Zhang, L.; Han, J.; Yang, M.; Xiao, X.; Zhang, Y.; Liu, H. Simultaneous Quantification of Niacin and Its Three Main Metabolites in Human Plasma by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2012, 904, 107–114. [Google Scholar] [CrossRef] [PubMed]
  67. Zhang, P.; Sun, Y.; Shi, G.; Sui, Y.; Li, Q.; Tang, Y.; Gu, J. Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers. Int. J. Anal. Chem. 2015, 2015, 212437. [Google Scholar] [CrossRef] [PubMed]
  68. Pittelli, M.; Formentini, L.; Faraco, G.; Lapucci, A.; Rapizzi, E.; Cialdai, F.; Romano, G.; Moneti, G.; Moroni, F.; Chiarugi, A. Inhibition of Nicotinamide Phosphoribosyltransferase: Cellular Bioenergetics Reveals a Mitochondrial Insensitive NAD Pool. J. Biol. Chem. 2010, 285, 34106–34114. [Google Scholar] [CrossRef] [PubMed]
  69. Sydenstricker, V.P. The History of Pellagra, Its Recognition as a Disorder of Nutrition and Its Conquest. Am. J. Clin. Nutr. 1958, 6, 409–414. [Google Scholar] [CrossRef] [PubMed]
  70. Gentilcore, D. Louis Sambon and the Clash of Pellagra Etiologies in Italy and the United States, 1905–1914. J. Hist. Med. Allied Sci. 2016, 19–42. [Google Scholar] [CrossRef] [PubMed]
  71. Kirkland, J.B.; Zempleni, J.; Suttie, J.W.; Gregory, J.F., III; Stover, P.J. (Eds.) Handbook of Vitamins, 5th ed.; CRC Press: Boca Raton, FL, USA, 2013; pp. 149–190. [Google Scholar]
  72. Jagielska, G.; Tomaszewicz-Libudzic, E.C.; Brzozowska, A. Pellagra: A Rare Complication of Anorexia Nervosa. Eur. Child. Adolesc. Psychiatry 2007, 16, 417–420. [Google Scholar] [CrossRef] [PubMed]
  73. Monteiro, J.P.; da Cunha, D.F.; Filho, D.C.; Silva-Vergara, M.L.; dos Santos, V.M.; da Costa, J.C., Jr.; Etchebehere, R.M.; Gonçalves, J.; de Carvalho da Cunha, S.F.; Jordão, A.A.; et al. Niacin Metabolite Excretion in Alcoholic Pellagra and AIDS Patients with and without Diarrhea. Nutrition 2004, 20, 778–782. [Google Scholar] [CrossRef] [PubMed]
  74. Park, S.M.; Li, T.; Wu, S.; Li, W.Q.; Weinstock, M.; Qureshi, A.A.; Cho, E. Niacin Intake and Risk of Skin Cancer in US Women and Men. Int. J. Cancer 2017, 140, 2023–2031. [Google Scholar] [CrossRef] [PubMed]
  75. Kirkland, J.B. Niacin Status and Treatment-Related Leukemogenesis. Mol. Cancer Ther. 2009, 8, 725–732. [Google Scholar] [CrossRef] [PubMed]
  76. Rosmaninho, A.; Sanches, M.; Fernandes, I.C.; Pinto-Almeida, T.; Vilaça, S.; Oliveira, A.; Selores, M. Letter: Pellagra as the Initial Presentation of Crohn Disease. Dermatol. Online J. 2012, 18, 12. [Google Scholar] [PubMed]
  77. Prakash, R.; Gandotra, S.; Singh, L.K.; Das, B.; Lakra, A. Rapid Resolution of Delusional Parasitosis in Pellagra with Niacin Augmentation Therapy. Gen. Hosp. Psychiatry 2008, 30, 581–584. [Google Scholar] [CrossRef] [PubMed]
  78. World Health Organization; United Nations High Commissions for Refugees. Pellagra and Its Prevention and Control in Major Emergencies. World Health Organization. 2000. Available online: (accessed on 1 December 2018 ).
  79. Altschul, R.; Hoffer, A.; Stephen, J.D. Influence of Nicotinic Acid on Serum Cholesterol in Man. Arch. Biochem. Biophys. 1955, 54, 558–559. [Google Scholar] [CrossRef]
  80. Zeman, M.; Vecka, M.; Perlík, F.; Staňková, B.; Hromádka, R.; Tvrzická, E.; Širc, J.; Hrib, J.; Žák, A. Pleiotropic Effects of Niacin: Current Possibilities for Its Clinical Use. Acta Pharm. 2016, 66, 449–469. [Google Scholar] [CrossRef] [PubMed]
  81. la Paz, S.M.; Bermudez, B.; Naranjo, M.C.; Lopez, S.; Abia, R.; Muriana, F.J. Pharmacological Effects of Niacin on Acute Hyperlipemia. Curr. Med. Chem. 2016, 23, 2826–2835. [Google Scholar] [CrossRef] [PubMed]
  82. Offermanns, S.; Colletti, S.L.; Lovenberg, T.W.; Semple, G.; Wise, A.; IJzerman, A.P. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, andGPR109B). Pharmacol. Rev. 2011, 63, 269–290. [Google Scholar] [CrossRef] [PubMed]
  83. Felts, A.S. Molecule of the Month. TREDAPTIVE (Nicotinic Acid/Laropiprant): A New Lipid-Modifying Therapy for the Treatment of LDL-C, HDL-C and Triglycerides. Curr. Top. Med. Chem. 2008, 8, 1310. [Google Scholar] [CrossRef] [PubMed]
  84. AIM-HIGH Investigators; Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N. Engl. J. Med. 2011, 365, 2255–2267. [Google Scholar] [CrossRef] [PubMed]
  85. HPS2-THRIVE Collaborative Group. HPS2-THRIVE Randomized Placebo-Controlled Trial in 25 673 High-Risk Patients of ER Niacin/Laropiprant: Trial Design, Pre-Specified Muscle and Liver Outcomes, and Reasons for Stopping Studytreatment. Eur. Heart J. 2013, 34, 1279–1291. [Google Scholar] [CrossRef]
  86. HPS2-THRIVE Collaborative Group; Landray, M.J.; Haynes, R.; Hopewell, J.C.; Parish, S.; Aung, T.; Tomson, J.; Wallendszus, K.; Craig, M.; Jiang, L.; et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N. Engl. J. Med. 2014, 371, 203–212. [Google Scholar] [CrossRef] [Green Version]
  87. Graff, E.C.; Fang, H.; Wanders, D.; Judd, R.L. Anti-inflammatory Effects of the Hydroxycarboxylic Acid Receptor 2. Metabolism 2016, 65, 102–113. [Google Scholar] [CrossRef] [PubMed]
  88. Yang, S.; Li, X.; Wang, N.; Yin, G.; Ma, S.; Fu, Y.; Wei, C.; Chen, Y.; Xu, W. GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation. Ann. Clin. Lab. Sci. 2015, 45, 315–322. [Google Scholar] [PubMed]
  89. Xu, X.; Lin, S.; Chen, Y.; Li, X.; Ma, S.; Fu, Y.; Wei, C.; Wang, C.; Xu, W. The Effect of Metformin on the Expression of GPR109A, NF-κB and IL-1β in Peripheral Blood Leukocytes from Patients with Type 2 Diabetes Mellitus. Ann. Clin. Lab. Sci. 2017, 47, 556–562. [Google Scholar] [PubMed]
  90. Heemskerk, M.M.; Dharuri, H.K.; van den Berg, S.A.; Jónasdóttir, H.S.; Kloos, D.P.; Giera, M.; van Dijk, K.W.; van Harmelen, V. Prolonged Niacin Treatment Leads to Increased Adipose Tissue PUFA Synthesis and Anti-Inflammatory Lipid and Oxylipin Plasmaprofile. J. Lipid Res. 2014, 55, 2532–2540. [Google Scholar] [CrossRef] [PubMed]
  91. Wanders, D.; Graff, E.C.; White, B.D.; Judd, R.L. Niacin Increases Adiponectin and Decreases Adipose Tissue Inflammation in High Fat Diet-Fed Mice. PLoS ONE 2013, 8, 71285. [Google Scholar] [CrossRef] [PubMed]
  92. Su, G.; Sun, G.; Liu, H.; Shu, L.; Zhang, J.; Guo, L.; Huang, C.; Xu, J. Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. Med. Sci. Monit. 2015, 21, 4081–4089. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Zhou, E.; Li, Y.; Yao, M.; Wei, Z.; Fu, Y.; Yang, Z. Niacin Attenuates the Production of Pro-Inflammatory Cytokines in LPS-Induced Mouse Alveolar Macrophages by HCA2 Dependent Mechanisms. Int. Immunopharmacol. 2014, 23, 121–126. [Google Scholar] [CrossRef] [PubMed]
  94. Cho, K.H.; Kim, H.J.; Rodriguez-Iturbe, B.; Vaziri, N.D. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am. J. Physiol. Ren. Physiol. 2009, 297, 106–113. [Google Scholar] [CrossRef] [PubMed]
  95. Jeong, K.Y.; Suh, G.J.; Kwon, W.Y.; Kim, K.S.; Jung, Y.S.; Kye, Y.C. The Therapeutic Effect and Mechanism of Niacin on Acute Lung Injury in a Rat Model of Hemorrhagic Shock: Down-Regulation of the Reactive Oxygen Species-Dependent Nuclear Factor κB Pathway. J. Trauma Acute Care Surg. 2015, 79, 247–255. [Google Scholar] [CrossRef] [PubMed]
  96. Godin, A.M.; Ferreira, W.C.; Rocha, L.T.; Ferreira, R.G.; Paiva, A.L.; Merlo, L.A.; Nascimento, E.B., Jr.; Bastos, L.F.; Coelho, M.M. Nicotinic Acid Induces Antinociceptive and Anti-Inflammatory Effects in Different Experimental Models. Pharmacol. BiochemBehav. 2012, 101, 493–498. [Google Scholar] [CrossRef] [PubMed]
  97. Ruddock, M.W.; Hirst, D.G. Nicotinamide Relaxes Vascular Smooth Muscle by Inhibiting Myosin Light Chain Kinase-Dependent Signaling Pathways: Implications for Anticancer Efficacy. Oncol. Res. 2004, 14, 483–489. [Google Scholar] [CrossRef] [PubMed]
  98. Ruddock, M.W.; Burns, D.M.; McKeown, S.R.; Murphy, L.; Walsh, I.K.; Keane, P.F.; Hirst, D.G. Contractile Properties of Human Renal Cell Carcinoma Recruited Arteries and Theirresponse to Nicotinamide. Radiother. Oncol. 2000, 54, 179–184. [Google Scholar] [CrossRef]
  99. Agote, M.; Viaggi, M.; Kreimann, E.; Krawiec, L.; Dagrosa, M.A.; Juvenal, G.J.; Pisarev, M.A. Influence of Nicotinamide on the Radiosensitivity of Normal and Goitrous Thyroid in the Rat. Thyroid 2001, 11, 1003–1007. [Google Scholar] [CrossRef] [PubMed]
  100. Hoskin, P.; Rojas, A.; Saunders, M. Accelerated Radiotherapy, Carbogen, and Nicotinamide (ARCON) in the Treatment of Advanced Bladder Cancer: Mature Results of a Phase II Nonrandomized Study. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1425–1431. [Google Scholar] [CrossRef] [PubMed]
  101. Williams, A.; Ramsden, D. Nicotinamide: A Double Edged Sword. Parkinsonism Relat. Disord. 2005, 11, 413–420. [Google Scholar] [CrossRef] [PubMed]
  102. Fricker, R.A.; Green, E.L.; Jenkins, S.I.; Griffin, S.M. The Influence of Nicotinamide on Health and Disease in the Central Nervous System. Int. J. Tryptophan Res. 2018, 11. [Google Scholar] [CrossRef] [PubMed]
  103. Turski, W.A.; Nakamura, M.; Todd, W.P.; Carpenter, B.K.; Whetsell, W.O., Jr.; Schwarcz, R. Identification and Quantification of Kynurenic Acid in Human Brain Tissue. Brain Res. 1988, 454, 164–169. [Google Scholar] [CrossRef]
  104. Gobaille, S.; Kemmel, V.; Brumaru, D.; Dugave, C.; Aunis, D.; Maitre, M. Xanthurenic Acid Distribution, Transport, Accumulation and Release in the Rat Brain. J. Neurochem. 2008, 105, 982–993. [Google Scholar] [CrossRef] [PubMed]
  105. Baran, H.; Schwarcz, R. Presence of 3-hydroxyanthranilic Acid in Rat Tissues and Evidence for Its Production from Anthranilic Acid in the Brain. J. Neurochem. 1990, 55, 738–744. [Google Scholar] [CrossRef] [PubMed]
  106. Fukui, S.; Schwarcz, R.; Rapoport, S.I.; Takada, Y.; Smith, Q.R. Blood-brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism. J. Neurochem. 1991, 56, 2007–2017. [Google Scholar] [CrossRef] [PubMed]
  107. Foster, A.C.; Collins, J.F.; Schwarcz, R. On the Excitotoxic Properties of Quinolinic Acid, 2,3-Piperidine Dicarboxylic Acids and Structurally Related Compounds. Neuropharmacology 1983, 22, 1331–1342. [Google Scholar] [CrossRef]
  108. Moroni, F.; Lombardi, G.; Carlà, V.; Moneti, G. The Excitotoxin Quinolinic Acid is Present and Unevenly Distributed in the Rat Brain. Brain Res. 1984, 19, 352–355. [Google Scholar] [CrossRef]
  109. Bohár, Z.; Toldi, J.; Fülöp, F.; Vécsei, L. Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations. Int. J. Mol. Sci. 2015, 16, 9772–9793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Majewski, M.; Kozlowska, A.; Thoene, M.; Lepiarczyk, E.; Grzegorzewski, W.J. Overview of the Role of Vitamins and Minerals on the Kynurenine Pathway in Health and Disease. J. Physiol. Pharmacol. 2016, 67, 3–19. [Google Scholar] [PubMed]
  111. Dang, Y.; Dale, W.E.; Brown, O.R. Comparative Effects of Oxygen on Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase of the Kynurenine Pathway. Free Radic. Biol. Med. 2000, 28, 615–624. [Google Scholar] [CrossRef]
  112. Kanai, M.; Nakamura, T.; Funakoshi, H. Identification and Characterization of Novel Variants of the Tryptophan 2,3-Dioxygenase Gene: Differential Regulation in the Mouse Nervous System During Development. Neurosci. Res. 2009, 64, 111–117. [Google Scholar] [CrossRef] [PubMed]
  113. Opitz, C.A.; Litzenburger, U.M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; et al. An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor. Nature 2011, 478, 197–203. [Google Scholar] [CrossRef] [PubMed]
  114. Lanz, T.V.; Williams, S.K.; Stojic, A.; Iwantscheff, S.; Sonner, J.K.; Grabitz, C.; Becker, S.; Böhler, L.I.; Mohapatra, S.R.; Sahm, F.; et al. Tryptophan-2,3-Dioxygenase (TDO) Deficiency is Associated with Subclinical Neuroprotection in a Mouse Model of Multiplesclerosis. Sci. Rep. 2017, 7, 41271. [Google Scholar] [CrossRef] [PubMed]
  115. O’Connor, J.C.; André, C.; Wang, Y.; Lawson, M.A.; Szegedi, S.S.; Lestage, J.; Castanon, N.; Kelley, K.W.; Dantzer, R. Interferon-Gamma and Tumor Necrosis Factor-Alpha Mediate the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-Like Behavior in Mice in Response to Bacillus Calmette-Guerin. J. Neurosci. 2009, 29, 4200–4209. [Google Scholar] [CrossRef] [PubMed]
  116. O’Connor, J.C.; Lawson, M.A.; André, C.; Briley, E.M.; Szegedi, S.S.; Lestage, J.; Castanon, N.; Herkenham, M.; Dantzer, R.; Kelley, K.W. Induction of IDO by Bacille Calmette-Guérin is Responsible for Development of Murine Depressive-Like Behavior. J. Immunol. 2009, 182, 3202–3212. [Google Scholar] [CrossRef] [PubMed]
  117. Corona, A.W.; Norden, D.M.; Skendelas, J.P.; Huang, Y.; O’Connor, J.C.; Lawson, M.; Dantzer, R.; Kelley, K.W.; Godbout, J.P. Indoleamine 2,3-Dioxygenase Inhibition Attenuates Lipopolysaccharide Induced Persistent Microglial Activation and Depressive-Like Complications in Fractalkine Receptor (CX(3)CR1)-Deficient Mice. Brain Behav. Immun. 2013, 31, 134–142. [Google Scholar] [CrossRef] [PubMed]
  118. Rharass, T.; Lantow, M.; Gbankoto, A.; Weiss, D.G.; Panáková, D.; Lucas, S. Ascorbic Acid Alters Cell Fate Commitment of Human Neural Progenitors in a WNT/β-Catenin/ROS Signaling Dependent Manner. J. Biomed. Sci. 2017, 16, 78. [Google Scholar] [CrossRef] [PubMed]
  119. Cataldi, S.; Arcuri, C.; Hunot, S.; Mecca, C.; Codini, M.; Laurenti, M.E.; Ferri, I.; Loreti, E.; Garcia-Gil, M.; Traina, G.; et al. Effect of Vitamin D in HN9.10e Embryonic Hippocampal Cells and in Hippocampus from MPTP-Induced Parkinson’s Disease Mouse Model. Front. Cell. Neurosci. 2018, 12, 31. [Google Scholar] [CrossRef] [PubMed]
  120. Cui, X.; Gooch, H.; Petty, A.; McGrath, J.J.; Eyles, D. Vitamin D and the Brain: Genomicand Non-Genomic Actions. Mol. Cell. Endocrinol. 2017, 453, 131–143. [Google Scholar] [CrossRef] [PubMed]
  121. Haushalter, C.; Asselin, L.; Fraulob, V.; Dollé, P.; Rhinn, M. Retinoic Acid Controls Early Neurogenesis in the Developing Mouse Cerebral Cortex. Dev. Biol. 2017, 430, 129–141. [Google Scholar] [CrossRef] [PubMed]
  122. Lin, Y.; Lin, Y.; Lin, H.; Chen, Y.; Wang, H.; Shi, J. Application of Propyl Gallate Alleviates Pericarp Browning in Harvested Longan Fruit by Modulating Metabolisms of Respiration and Energy. Food Chem. 2018, 240, 863–869. [Google Scholar] [CrossRef] [PubMed]
  123. Griffin, S.M.; Pickard, M.R.; Orme, R.P.; Hawkins, C.P.; Fricker, R.A. Nicotinamide Promotes Neuronal Differentiation of Mouse Embryonic Stem Cells in Vitro. Neuroreport 2013, 24, 1041–1046. [Google Scholar] [CrossRef] [PubMed]
  124. Griffin, S.M.; Pickard, M.R.; Orme, R.P.; Hawkins, C.P.; Williams, A.C.; Fricker, R.A. Nicotinamide Alone Accelerates the Conversion of Mouse Embryonic Stem Cells into Mature Neuronal Populations. PLoS ONE 2017, 12, e0183358. [Google Scholar] [CrossRef] [PubMed]
  125. Sperber, H.; Mathieu, J.; Wang, Y.; Ferreccio, A.; Hesson, J.; Xu, Z.; Fischer, K.A.; Devi, A.; Detraux, D.; Gu, H.; et al. The Metabolome Regulates the Epigenetic Landscape During Naive-to-Primed Human Embryonic Stem Cell Transition. Nat. Cell Biol. 2015, 17, 1523–1535. [Google Scholar] [CrossRef] [PubMed]
  126. Chong, Z.Z.; Lin, S.H.; Maiese, K. The NAD+ Precursor Nicotinamide Governs Neuronal Survival During Oxidative Stress Through Protein Kinase B Coupled to FOXO3a and Mitochondrial Membrane Potential. J. Cereb. Blood Flow Metab. 2004, 24, 728–743. [Google Scholar] [CrossRef] [PubMed]
  127. Zhang, W.; Xie, Y.; Wang, T.; Bi, J.; Li, H.; Zhang, L.Q.; Ye, S.Q.; Ding, S. Neuronal Protective Role of PBEF in a Mouse Model of Cerebral Ischemia. J. Cereb. Blood Flow Metab. 2010, 30, 1962–1971. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Wang, X.; Zhang, Q.; Bao, R.; Zhang, N.; Wang, Y.; Polo-Parada, L.; Tarim, A.; Alemifar, A.; Han, X.; Wilkins, H.M.; et al. Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. Cell Rep. 2017, 20, 2184–2200. [Google Scholar] [CrossRef] [PubMed]
  129. Conforti, L.; Gilley, J.; Coleman, M.P. Wallerian Degeneration: An Emerging Axon Death Pathway Linking Injury and Disease. Nat. Rev. Neurosci. 2014, 15, 394–409. [Google Scholar] [CrossRef] [PubMed]
  130. Loreto, A.; Di Stefano, M.; Gering, M.; Conforti, L. Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca2+ Influx butOnly Modestly Influenced by Mitochondria. Cell Rep. 2015, 13, 2539–2552. [Google Scholar] [CrossRef] [PubMed]
  131. Liu, H.W.; Smith, C.B.; Schmidt, M.S.; Cambronne, X.A.; Cohen, M.S.; Migaud, M.E.; Brenner, C.; Goodman, R.H. Pharmacological Bypass of NAD(+) Salvage Pathway Protects Neurons from Chemotherapy-induced Degeneration. Proc. Natl. Acad. Sci. USA 2018, 115, 10654–10659. [Google Scholar] [CrossRef] [PubMed]
  132. Araki, T.; Sasaki, Y.; Milbrandt, J. Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration. Science 2004, 305, 1010–1013. [Google Scholar] [CrossRef] [PubMed]
  133. Gilley, J.; Coleman, M.P. Endogenous Nmnat2 Is an Essential Survivalfactor for Maintenance of Healthy Axons. PLoS Biol. 2010, 8, e1000300. [Google Scholar] [CrossRef] [PubMed]
  134. Kumar, A.; Singh, A.; Ekavali, E. A Review on Alzheimer’s Disease Pathophysiology and Its Management: An Update. Pharmacol. Rep. 2015, 67, 195–203. [Google Scholar] [CrossRef] [PubMed]
  135. Morris, M.C.; Evans, D.A.; Bienias, J.L.; Scherr, P.A.; Tangney, C.C.; Hebert, L.E.; Bennett, D.A.; Wilson, R.S.; Aggarwal, N. Dietary Niacin and Risk of Incident Alzheimer’s Disease and of Cognitive Decline. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1093–1099. [Google Scholar] [CrossRef] [PubMed]
  136. Morris, M.C.; Schneider, J.A.; Tangney, C.C. Thoughts on B-vitamins and Dementia. J. Alzheimers Dis. 2006, 9, 429–433. [Google Scholar] [CrossRef] [PubMed]
  137. Williams, A.C.; Hill, L.J.; Ramsden, D.B. Nicotinamide, NAD(P)(H), and Methylgroup Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra. Curr. Gerontol. Geriatr. Res. 2012, 2012, 302875. [Google Scholar] [CrossRef]
  138. Kerr, J.S.; Adriaanse, B.A.; Greig, N.H.; Mattson, M.P.; Cader, M.Z.; Bohr, V.A.; Fang, E.F. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 2017, 40, 151–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  139. Liu, D.; Pitta, M.; Jiang, H.; Le, J.H.; Zhang, G.; Chen, X.; Kawamoto, E.M.; Mattson, M.P. Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession. Neurobiol. Aging 2013, 34, 1564–1580. [Google Scholar] [CrossRef] [PubMed]
  140. Wang, X.; Hu, X.; Yang, Y.; Takata, T.; Sakurai, T. Nicotinamide Mononucleotide Protects Against β-Amyloid Oligomer-Induced Cognitive Impairment and Neuronal Death. Brain Res. 2016, 1643, 1–9. [Google Scholar] [CrossRef] [PubMed]
  141. Kim, E.J.; Yang, S.J. Nicotinamide Reduces Amyloid Precursor Protein and Presenilin 1 in Brain Tissues of Amyloid Beta-Tail Vein Injected Mice. Clin. Nutr. Res. 2017, 6, 130–135. [Google Scholar] [CrossRef] [PubMed]
  142. Hou, Y.; Lautrup, S.; Cordonnier, S.; Wang, Y.; Croteau, D.L.; Zavala, E.; Zhang, Y.; Moritoh, K.; O’Connell, J.F.; Baptiste, B.A.; et al. NAD+ Supplementation Normalizes Key Alzheimer’s Features and DNA Damage Responses in a New AD Mouse Model with Introduced DNA Repair Deficiency. Proc. Natl. Acad. Sci. USA 2018, 115, 1876–1885. [Google Scholar] [CrossRef] [PubMed]
  143. Wencel, P.L.; Lukiw, W.J.; Strosznajder, J.B.; Strosznajder, R.P. Inhibition of poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity. Mol. Neurobiol. 2018, 55, 4612–4623. [Google Scholar] [CrossRef] [PubMed]
  144. Cornelius, C.; Trovato Salinaro, A.; Scuto, M.; Fronte, V.; Cambria, M.T.; Pennisi, M.; Bella, R.; Milone, P.; Graziano, A.; Crupi, R.; et al. Cellular Stress Response, Sirtuins and UCP Proteins in Alzheimer Disease: Role of Vitagenes. Immun. Ageing 2013, 10, 41. [Google Scholar] [CrossRef] [PubMed]
  145. Rizzi, L.; Roriz-Cruz, M. Sirtuin 1 and Alzheimer’s Disease: An Up-To-Date Review. Neuropeptides 2018, 71, 54–60. [Google Scholar] [CrossRef] [PubMed]
  146. Ljungberg, M.C.; Ali, Y.O.; Zhu, J.; Wu, C.S.; Oka, K.; Zhai, R.G.; Lu, H.C. CREB-Activity and NMNAT2 Transcription are Down-Regulated Prior to Neurodegeneration, while NMNAT2 Overexpression is Neuroprotective, in a Mouse Model of Human Tauopathy. Hum. Mol. Genet. 2012, 21, 251–267. [Google Scholar] [CrossRef] [PubMed]
  147. Ali, Y.O.; Allen, H.M.; Yu, L.; Li-Kroeger, D.; Bakhshizadehmahmoudi, D.; Hatcher, A.; McCabe, C.; Xu, J.; Bjorklund, N.; Taglialatela, G.; et al. NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. PLoS Biol. 2016, 14, e1002472. [Google Scholar] [CrossRef] [PubMed]
  148. Wakade, C.; Chong, R.; Bradley, E.; Thomas, B.; Morgan, J. Upregulation of GPR109A in Parkinson’s Disease. PLoS ONE 2014, 9, e109818. [Google Scholar] [CrossRef] [PubMed]
  149. Aaseth, J.; Dusek, P.; Roos, P.M. Prevention of Progression in Parkinson’s Disease. Biometals 2018, 31, 737–747. [Google Scholar] [CrossRef] [PubMed]
  150. Anderson, D.W.; Bradbury, K.A.; Schneider, J.S. Broad Neuroprotective Profile of Nicotinamide in Different Mouse Models of MPTP-Induced Parkinsonism. Eur. J. Neurosci. 2008, 28, 610–617. [Google Scholar] [CrossRef] [PubMed]
  151. Wakade, C.; Giri, B.; Malik, A.; Khodadadi, H.; Morgan, J.C.; Chong, R.K.; Baban, B. Niacin Modulates Macrophage Polarization in Parkinson’s Disease. J. Neuroimmunol. 2018, 320, 76–79. [Google Scholar] [CrossRef] [PubMed]
  152. Zhou, Y.; Wu, J.; Sheng, R.; Li, M.; Wang, Y.; Han, R.; Han, F.; Chen, Z.; Qin, Z.H. Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity. Neuroscience 2018, 391, 140–153. [Google Scholar] [CrossRef] [PubMed]
  153. Parsons, R.B.; Smith, M.L.; Williams, A.C.; Ramsden, D.B. Expression of Nicotinamide N-Methyltransferase (E.C. in the Parkinsonian Brain. J. Neurol. Exp. Neurol. 2002, 61, 111–124. [Google Scholar] [CrossRef] [Green Version]
  154. Parsons, R.B.; Smith, S.W.; Waring, R.H.; Williams, A.C.; Ramsden, D.B. High Expression of Nicotinamide N-Methyltransferase in Patients with Idiopathic Parkinson’s Disease. Neurosci. Lett. 2003, 342, 13–16. [Google Scholar] [CrossRef]
  155. Williams, A.C.; Cartwright, L.S.; Ramsden, D.B. Parkinson’s Disease: The First Common Neurological Disease due to Auto-Intoxication? QJM 2005, 98, 215–226. [Google Scholar] [CrossRef] [PubMed]
  156. Thomas, M.G.; Saldanha, M.; Mistry, R.J.; Dexter, D.T.; Ramsden, D.B.; Parsons, R.B. Nicotinamide N-Methyltransferase Expression in SH-SY5Y Neuroblastoma and N27 Mesencephalic Neurones Induces Changes in Cell Morphology via Ephrin-B2 and Aktsignalling. Cell Death Dis. 2013, 4, 669. [Google Scholar] [CrossRef] [PubMed]
  157. Singh, V.; Sharma, R.K.; Athilingam, T.; Sinha, P.; Sinha, N.; Thakur, A.K. NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington’s Disease Suggests Altered Cell Energetics. J. Proteome Res. 2017, 16, 3863–3872. [Google Scholar] [CrossRef] [PubMed]
  158. Ghosh, S.; Feany, M.B. Comparison of Pathways Controlling Toxicity in the Eye and Brain in Drosophila Models of Human Neurodegenerative Diseases. Hum. Mol. Genet. 2004, 13, 2011–2018. [Google Scholar] [CrossRef] [PubMed]
  159. Hathorn, T.; Snyder-Keller, A.; Messer, A. Nicotinamide Improves Motor Deficits and Upregulates PGC-1α and BDNF Gene Expression in a Mouse Model of Huntington’s Disease. Neurobiol. Dis. 2011, 41, 43–50. [Google Scholar] [CrossRef] [PubMed]
  160. Sidhu, A.; Diwan, V.; Kaur, H.; Bhateja, D.; Singh, C.K.; Sharma, S.; Padi, S.S.V. Nicotinamide Reverses Behavioral Impairments and Provides Neuroprotection in 3-Nitropropionic Acid Induced Animal Model of Huntington’s Disease: Implication of Oxidative Stress- Poly(ADP- Ribose) Polymerase Pathway. Metab. Brain Dis. 2018, 33, 1911–1921. [Google Scholar] [CrossRef] [PubMed]
  161. Chidambaram, S.B.; Vijayan, R.; Sekar, S.; Mani, S.; Rajamani, B.; Ganapathy, R. Simultaneous Blockade of NMDA Receptors and PARP-1 Activity Synergistically Alleviate Immunoexcitotoxicity and Bioenergetics in 3-Nitropropionic Acid Intoxicated Mice: Evidences from Memantine and 3-Aminobenzamide Interventions. Eur. J. Pharmacol. 2017, 803, 148–158. [Google Scholar] [CrossRef] [PubMed]
  162. Suzuki, E.; Okuda, H.; Nishida, K.; Fujimoto, S.; Nagasawa, K. Protective Effect of Nicotinamide Against Poly(ADP-Ribose) Polymerase-1-Mediated Astrocyte Death Depends on Its Transporter-Mediated Uptake. Life Sci. 2010, 86, 676–682. [Google Scholar] [CrossRef] [PubMed]
  163. Sadri-Vakili, G.; Cha, J.H. Histone Deacetylase Inhibitors: A Novel Therapeutic Approach to Huntington’s Disease (Complex Mechanism of Neuronal Death). Curr. Alzheimer Res. 2006, 3, 403–408. [Google Scholar] [CrossRef] [PubMed]
  164. Pallos, J.; Bodai, L.; Lukacsovich, T.; Purcell, J.M.; Steffan, J.S.; Thompson, L.M.; Marsh, J.L. Inhibition of Specific HDACs and Sirtuins Suppresses Pathogenesis in a Drosophila Model of Huntington’s Disease. Hum. Mol. Genet. 2008, 17, 3767–3775. [Google Scholar] [CrossRef] [PubMed]
  165. Verdin, E. NAD+ in Aging, Metabolism, and Neurodegeneration. Science 2015, 350, 1208–1213. [Google Scholar] [CrossRef] [PubMed]
  166. Bonkowski, M.S.; Sinclair, D.A. Slowing Ageing by Design: The Rise of NAD. Nat. Rev. Mol. Cell Biol. 2016, 17, 679–690. [Google Scholar] [CrossRef] [PubMed]
  167. Jęśko, H.; Wencel, P.; Strosznajder, R.P.; Strosznajder, J.B. Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders. Neurochem. Res. 2017, 42, 876–890. [Google Scholar] [CrossRef] [PubMed]
  168. Williams, A.C.; Ramsden, D.B. Autotoxicity, Methylation and a Road to the Prevention of Parkinson’s Disease. J. Clin. Neurosci. 2005, 12, 6–11. [Google Scholar] [CrossRef] [PubMed]
  169. Lehmann, S.; Loh, S.H.; Martins, L.M. Enhancing NAD(+) Salvage Metabolism is Neuroprotective in a PINK1 Model of Parkinson’s Disease. Biol. Open 2017, 6, 141–147. [Google Scholar] [CrossRef] [PubMed]
  170. Testa, C.M.; Jankovic, J. Huntington Disease: A Quarter Century of Progress Since the Gene Discovery. J. Neurol. Sci. 2019, 396, 52–68. [Google Scholar] [CrossRef] [PubMed]
  171. McColgan, P.; Tabrizi, S.J. Huntington’s Disease: A Clinical Review. Eur. J. Neurol. 2018, 25, 24–34. [Google Scholar] [CrossRef] [PubMed]
  172. Tulino, R.; Benjamin, A.C.; Jolinon, N.; Smith, D.L.; Chini, E.N.; Carnemolla, A.; Bates, G.P. SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington’s Disease Mice. PLoS ONE 2016, 11, e0145425. [Google Scholar] [CrossRef] [Green Version]
  173. Naia, L.; Rosenstock, T.R.; Oliveira, A.M.; Oliveira-Sousa, S.I.; Caldeira, G.L.; Carmo, C.; Laço, M.N.; Hayden, M.R.; Oliveira, C.R.; Rego, A.C. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington’s Disease Models. Mol. Neurobiol. 2017, 54, 5385–5399. [Google Scholar] [CrossRef] [PubMed]
  174. Harrison, I.F.; Powell, N.M.; Dexter, D.T. The Histone Deacetylase Inhibitor Nicotinamide Exacerbates Neurodegeneration in the Lactacystin Rat Model of Parkinson’s Disease. J. Neurochem. 2019, 148, 136–156. [Google Scholar] [CrossRef] [PubMed]
  175. Hoane, M.R.; Akstulewicz, S.L.; Toppen, J. Treatment with Vitamin B3 Improves Functional Recovery and Reduces GFAP Expression Following Traumatic Brain Injury in Rats. J. Neurotrauma 2003, 20, 1189–1199. [Google Scholar] [CrossRef] [PubMed]
  176. Goffus, A.M.; Anderson, G.D.; Hoane, M. Sustained Delivery of Nicotinamide Limits Cortical Injury and Improves Functional Recovery Following Traumatic Brain Injury. Oxid. Med. Cell. Longev. 2010, 3, 145–152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  177. Vonder Haar, C.; Maas, W.R.; Jacobs, E.A.; Hoane, M.R. Deficits in Discrimination after Experimental Frontal Brain Injury Are Mediated by Motivation and Can Be Improved by Nicotinamide Administration. J. Neurotrauma 2014, 31, 1711–1720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  178. Vonder Haar, C.; Anderson, G.D.; Hoane, M.R. Continuous Nicotinamide Administration Improves Behavioral Recovery and Reduces Lesion Size Following Bilateral Frontal Controlled Cortical Impact Injury. Behav. Brain Res. 2011, 224, 311–317. [Google Scholar] [CrossRef] [PubMed]
  179. Won, S.J.; Choi, B.Y.; Yoo, B.H.; Sohn, M.; Ying, W.; Swanson, R.A.; Suh, S.W. Prevention of Traumatic Brain Injury-Induced Neuron Death by Intranasal Delivery of Nicotinamide Adenine Dinucleotide. J. Neurotrauma 2012, 29, 1401–1409. [Google Scholar] [CrossRef] [PubMed]
  180. Swan, A.A.; Chandrashekar, R.; Beare, J.; Hoane, M.R. Preclinical Efficacy Testing in Middle-Aged Rats: Nicotinamide, a Novel Neuroprotectant, Demonstrates Diminished Preclinical Efficacy after Controlled Cortical Impact. J. Neurotrauma 2011, 28, 431–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  181. Kwon, W.Y.; Suh, G.J.; Kim, K.S.; Lee, H.J.; Jeong, K.Y.; Kwak, Y.H.; Kim, K. Niacin Suppresses the Mitogen-Activated Protein Kinase Pathway and Attenuates Brain Injury after Cardiac Arrest in Rats. Crit. Care Med. 2013, 41, e223–e232. [Google Scholar] [CrossRef] [PubMed]
  182. Park, J.H.; Long, A.; Owens, K.; Kristian, T. Nicotinamide Mononucleotide Inhibits Post-Ischemic NAD(+) Degradation and Dramatically Ameliorates Brain Damage Following Global Cerebral Ischemia. Neurobiol. Dis. 2016, 95, 102–110. [Google Scholar] [CrossRef] [PubMed]
  183. Shetty, P.K.; Galeffi, F.; Turner, D.A. Nicotinamide Pre-treatment Ameliorates NAD(H) Hyperoxidation and Improves Neuronal Function after Severe Hypoxia. Neurobiol. Dis. 2014, 62, 469–478. [Google Scholar] [CrossRef] [PubMed]
  184. Chen, J.; Cui, X.; Zacharek, A.; Jiang, H.; Roberts, C.; Zhang, C.; Lu, M.; Kapke, A.; Feldkamp, C.S.; Chopp, M. Niaspan Increases Angiogenesis and Improves Functional Recovery after Stroke. Ann. Neurol. 2007, 62, 49–58. [Google Scholar] [CrossRef] [PubMed]
  185. Chen, J.; Cui, X.; Zacharek, A.; Ding, G.L.; Shehadah, A.; Jiang, Q.; Lu, M.; Chopp, M. Niaspan Treatment Increases Tumor Necrosis Factor-Alpha-Converting Enzyme and Promotes Arteriogenesis after Stroke. J. Cereb. Blood Flow Metab. 2009, 29, 911–920. [Google Scholar] [CrossRef] [PubMed]
  186. Kwon, W.Y.; Suh, G.J.; Kim, K.S.; Jung, Y.S.; Kim, S.H.; Lee, A.R.; You, K.M.; Park, M.J. Niacin and Selenium Attenuate Brain Injury After Cardiac Arrest in Rats by Up-Regulating DJ-1-Akt Signaling. Crit. Care Med. 2018, 46, e788–e796. [Google Scholar] [CrossRef] [PubMed]
  187. Peterson, T.C.; Anderson, G.D.; Kantor, E.D.; Hoane, M.R. A Comparison of the Effects of Nicotinamide and Progesterone on Functional Recovery of Cognitive Behavior Following Cortical Contusion Injury in the Rat. J. Neurotrauma 2012, 29, 2823–2830. [Google Scholar] [CrossRef] [PubMed]
  188. Peterson, T.C.; Hoane, M.R.; McConomy, K.S.; Farin, F.M.; Bammler, T.K.; MacDonald, J.W.; Kantor, E.D.; Anderson, G.D. A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. J. Neurotrauma 2015, 32, 765–779. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  189. Wang, P.; Xu, T.Y.; Guan, Y.F.; Tian, W.W.; Viollet, B.; Rui, Y.C.; Zhai, Q.W.; Su, D.F.; Miao, C.Y. Nicotinamide Phosphoribosyltransferase Protects against Ischemic Stroke through SIRT1-Dependent Adenosine Monophosphate-Activated Kinase Pathway. Ann. Neurol. 2011, 69, 360–374. [Google Scholar] [CrossRef] [PubMed]
  190. Zhang, T.; Kraus, W.L. SIRT1-Dependent Regulation of Chromatin and Transcription: Linking NAD(+) Metabolism and Signaling to the Control of Cellular Functions. Biochim. Biophys. Acta 2010, 1804, 1666–1675. [Google Scholar] [CrossRef] [PubMed]
  191. Jing, Z.; Xing, J.; Chen, X.; Stetler, R.A.; Wen, Z.; Gan, Y.; Zhang, F.; Gao, Y.; Chen, J.; Leak, R.K.; et al. Neuronal NAMPT is Released after Cerebral Ischemia and Protects against White Matter Injury. J. Cereb. Blood Flow Metab. 2014, 34, 1613–1621. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  192. Hardison, W.R.; Yorns, H.H., Jr. Mitochondrial Dysfunction in Migraine. Semin. Pediatr. Neurol. 2013, 20, 188–193. [Google Scholar]
  193. Neri, M.; Frustaci, A.; Milic, M.; Valdiglesias, V.; Fini, M.; Bonassi, S.; Barbanti, P. A Meta-Analysis of Biomarkers Related to Oxidative Stress and Nitric Oxide Pathway in Migraine. Cephalalgia 2015, 35, 931–937. [Google Scholar] [CrossRef] [PubMed]
  194. Bohár, Z.; Párdutz, Á.; Vécsei, L. Tryptophan Catabolites and Migraine. Curr. Pharm. Des. 2016, 22, 1013–1021. [Google Scholar] [CrossRef] [PubMed]
  195. Morrow, J.D.; Awad, J.A.; Oates, J.A.; Roberts, L.J. Identification of Skin as a Major Site on Prostaglandin D2 Release Following Oral Administration of Niacin in Humans. J. Investig. Dermatol. 1992, 98, 812–815. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  196. Morrow, J.D.; Parsons, W.G.; Roberts, L., II. Release of Markedly Increased Quantities of Prostaglandin D2 in Vivo in Humans Following the Administration of Nicotinic Acid. Prostaglandins 1989, 38, 263–274. [Google Scholar] [CrossRef]
  197. Kim, E.J.; Lim, S.Y.; Lee, H.J.; Lee, J.Y.; Choi, S.; Kim, S.Y.; Kim, J.M.; Shin, I.S.; Yoon, J.S.; Yang, S.J.; et al. Low Dietary Intake of n-3 Fatty Acids, Niacin, Folate, and Vitamin C in Korean Patients with Schizophrenia and the Development of Dietary Guidelines for Schizophrenia. Nutr. Res. 2017, 45, 10–18. [Google Scholar] [CrossRef] [PubMed]
  198. Cao, B.; Sun, X.Y.; Zhang, C.B.; Yan, J.J.; Zhao, Q.Q.; Yang, S.Y.; Yan, L.L.; Huang, N.H.; Zeng, J.; Liao, J.Y.; et al. Association Between B Vitamins and Schizophrenia: A Population-Based Case-Control Study. Psychiatry Res. 2018, 259, 501–505. [Google Scholar] [CrossRef] [PubMed]
  199. Jonsson, B.H. Nicotinic Acid Long-Term Effectiveness in a Patient with Bipolar Type II Disorder: A Case of Vitamin Dependency. Nutrients 2018, 10, 134. [Google Scholar] [CrossRef] [PubMed]
  200. Ryou, M.G.; Mallet, R.T. An In Vitro Oxygen-Glucose Deprivation Model for Studying Ischemia-Reperfusion Injury of Neuronal Cells. Methods Mol. Biol. 2018, 1717, 229–235. [Google Scholar] [CrossRef]
  201. Martin, E.; Rosenthal, R.E.; Fiskum, G. Pyruvate Dehydrogenase Complex: Metabolic Link to Ischemic Brain Injury and Target of Oxidative Stress. J. Neurosci. Res. 2005, 79, 240–247. [Google Scholar] [CrossRef] [PubMed]
  202. Mokudai, T.; Ayoub, I.A.; Sakakibara, Y.; Lee, E.J.; Ogilvy, C.S.; Maynard, K.I. Delayed Treatment with Nicotinamide (Vitamin B3) Improves Neurological Outcome and Reduces Infarct Volume after Transient Focal Cerebral Ischemia in Wistar Rats. Stroke 2000, 31, 1679–1685. [Google Scholar] [CrossRef] [PubMed]
  203. Ayoub, I.A.; Lee, E.J.; Ogilvy, C.S.; Beal, M.F.; Maynard, K.I. Nicotinamide Reduces Infarction up to Two Hours after the Onset of Permanent Focal Ischemia in Wistar Rats. Neurosci. Lett. 1999, 259, 21–24. [Google Scholar] [CrossRef]
  204. Sakakibara, Y.; Mitha, A.P.; Ogilvy, C.S.; Maynard, K.I. Post-Treatment with Nicotinamide (Vitamin B3) Reduces the Infarct Volume Following Permanent Focal Ischemia in Female Sprague–Dawley and Wistar Rats. Neurosci. Lett. 2000, 281, 111–114. [Google Scholar] [CrossRef]
  205. Sakakibara, Y.; Mitha, A.P.; Ayoub, I.A.; Ogilvy, C.S.; Maynard, K.I. Delayed Treatment with Nicotinamide (Vitamin B3) Reduces the Infarct Volume Following Focal Cerebral Ischemia in Spontaneously Hypertensive Rats, Diabetic and Non-Diabetic Fischer 344 Rats. Brain Res. 2002, 931, 68–73. [Google Scholar] [CrossRef]
  206. Feng, Y.; Paul, I.A.; LeBlanc, M.H. Nicotinamide Reduces Hypoxic Ischemic Brain Injury in the Newborn Rat. Brain Res. Bull. 2006, 69, 117–122. [Google Scholar] [CrossRef] [PubMed]
  207. Rizzoli, P.; Mullally, W.J. Headache. Am. J. Med. 2018, 131, 17–24. [Google Scholar] [CrossRef] [PubMed]
  208. Close Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd Edition. Cephalalgia 2013, 33, 629–808. [Google Scholar] [CrossRef] [PubMed]
  209. Nattagh-Eshtivani, E.; Sani, M.A.; Dahri, M.; Ghalichi, F.; Ghavami, A.; Arjang, P.; Tarighat-Esfanjani, A. The Role of Nutrients in the Pathogenesis and Treatment of Migraine Headaches: Review. Biomed. Pharmacother. 2018, 102, 317–325. [Google Scholar] [CrossRef] [PubMed]
  210. Goldzieher, J.W.; Popkin, G.L. Treatment of Headache with Intravenous Sodium Nicotinate. J. Am. Med. Assoc. 1946, 131, 103–105. [Google Scholar] [CrossRef] [PubMed]
  211. Grenfell, R.F. Treatment of Migraine with Nicotinic Acid. Am. Pract Dig. Treat. 1949, 3, 542–544. [Google Scholar] [PubMed]
  212. Grenfell, R.F. Treatment of Tension Headache. Am. Pract. Dig. Treat. 1951, 2, 933–936. [Google Scholar] [PubMed]
  213. Morgan, Z.R. Nicotinic Acid Therapy in Vasoconstriction Type of Headache. Md. State Med. J. 1953, 2, 377–382. [Google Scholar] [PubMed]
  214. Morgan, Z.R. A Newer Method of Nicotinic Acid Therapy in Headache of the Vasoconstrictive Type. J. Am. Geriatr. Soc. 1955, 3, 545–551. [Google Scholar] [CrossRef] [PubMed]
  215. Prousky, J.; Seely, D. The Treatment of Migraines and Tension-Type Headaches with Intravenous and Oral Niacin (Nicotinic Acid): Systematic Review of the Literature. Nutr. J. 2005, 4, 3. [Google Scholar] [CrossRef] [PubMed]
  216. Oxenkrug, G.F. Tryptophan Kynurenine Metabolism as a Common Mediator of Genetic and Environmental Impacts in Major Depressive Disorder: The Serotonin Hypothesis Revisited 40 Years Later. Isr. J. Psychiatry Relat. Sci. 2010, 47, 56–63. [Google Scholar] [CrossRef] [PubMed]
  217. Myint, A.M.; Schwarz, M.J.; Müller, N. The Role of the Kynurenine Metabolism in Major Depression. J. Neural Transm. 2012, 119, 245–251. [Google Scholar] [CrossRef] [PubMed]
  218. Wonodi, I.; Schwarcz, R. Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia. Schizophr. Bull. 2010, 36, 211–218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  219. Miller, C.L.; Llenos, I.C.; Cwik, M.; Walkup, J.; Weis, S. Alterations in Kynurenine Precursor and Product Levels in Schizophrenia and Bipolar Disorder. Neurochem. Int. 2008, 52, 1297–1303. [Google Scholar] [CrossRef] [PubMed]
  220. Savitz, J.; Drevets, W.C.; Smith, C.M.; Victor, T.A.; Wurfel, B.E.; Bellgowan, P.S.; Bodurka, J.; Teague, T.K.; Dantzer, R. Putative Neuroprotective and Neurotoxic Kynurenine Pathway Metabolites are Associated with Hippocampal and Amygdalar Volumes in Subjects with Major Depressive Disorder. Neuropsychopharmacology 2015, 40, 463–471. [Google Scholar] [CrossRef] [PubMed]
  221. Kanai, M.; Funakoshi, H.; Takahashi, H.; Hayakawa, T.; Mizuno, S.; Matsumoto, K.; Nakamura, T. Tryptophan 2,3-Dioxygenase is a Key Modulator of Physiological Neurogenesis and Anxiety-Related Behavior in Mice. Mol. Brain 2009, 2, 8. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Chemical structures of niacin vitamers (A) and active coenzymatic forms (B). NAD: nicotinamide adenin dinucleotide. NADP: nicotinamide adenin dinucleotide phosphate.
Figure 1. Chemical structures of niacin vitamers (A) and active coenzymatic forms (B). NAD: nicotinamide adenin dinucleotide. NADP: nicotinamide adenin dinucleotide phosphate.
Ijms 20 00974 g001
Figure 2. De novo synthesis of NAD(P) from tryptophan, nicotinamide and nicotinic acid. (1) Two iron porphyrin metalloproteins, tryptophan 2,3 dioxygenase (TDO, in the liver) and indolamine-pyrrole 2-3 dioxygenase (IDO, in extrahepatic tissues), oxidize the pyrrole moiety of Tryptophan (Trp), thus forming N-L-formylkynurenine. (2) Arylformamidase (AFMID) hydrolytically removes the formyl group producing kynurenine and is then (3) hydroxylated to 3-hydroxykynurenine by kynurenine-3 monooxygenase (KMO), a mitochondrial flavo-enzyme that uses O2 as a substrate and NADPH as a cofactor. The action of (4) kynureninase B (KYNU, a vitamin B6-dependent enzyme) and (5) 3-hydroxyanthranilic dioxygenase (HAAO, a nonheme iron-dependent dioxygenase) leads to production of 2-amino-3-carboxymuconic-6-semialdehyde acid, an unstable product that (6) spontaneously condensates and rearranges to form quinolinic acid; then, (7) quinolinic acid is decarboxylated and converted to nicotinic acid mononucleotide by quinolinic acid phosphoribosyltransferase (QPRT). Nicotinic acid mononucleotide is also produced through the “salvage pathway”, via the action of (8) nicotinic acid phosphoribosyltransferase (NPRT). The subsequent action of (9) nicotinamide/nicotinic acid-mononucleotide-adenylyltransferases (NMNAT1-3) and (10) NAD synthetase (NADSYN1) leads to the generation of NAD, which is then (11) phosphorylated to produce NADP. NAD can also derive directly from nicotinamide through the action of (12) nicotinamide phosphoribosyltransferase (NAMPT) and (13) nicotinamide/nicotinic acid-mononucleotide-adenylyltransferase (NMNAT1-3). Red frames: dietary precursors of NAD(P). Ala: alanine; Gln: glutamine; Glu: glutamate; PLP pyridoxal phosphate; PRPP: 5-phosphoribosyl-1- pyrophosphate.
Figure 2. De novo synthesis of NAD(P) from tryptophan, nicotinamide and nicotinic acid. (1) Two iron porphyrin metalloproteins, tryptophan 2,3 dioxygenase (TDO, in the liver) and indolamine-pyrrole 2-3 dioxygenase (IDO, in extrahepatic tissues), oxidize the pyrrole moiety of Tryptophan (Trp), thus forming N-L-formylkynurenine. (2) Arylformamidase (AFMID) hydrolytically removes the formyl group producing kynurenine and is then (3) hydroxylated to 3-hydroxykynurenine by kynurenine-3 monooxygenase (KMO), a mitochondrial flavo-enzyme that uses O2 as a substrate and NADPH as a cofactor. The action of (4) kynureninase B (KYNU, a vitamin B6-dependent enzyme) and (5) 3-hydroxyanthranilic dioxygenase (HAAO, a nonheme iron-dependent dioxygenase) leads to production of 2-amino-3-carboxymuconic-6-semialdehyde acid, an unstable product that (6) spontaneously condensates and rearranges to form quinolinic acid; then, (7) quinolinic acid is decarboxylated and converted to nicotinic acid mononucleotide by quinolinic acid phosphoribosyltransferase (QPRT). Nicotinic acid mononucleotide is also produced through the “salvage pathway”, via the action of (8) nicotinic acid phosphoribosyltransferase (NPRT). The subsequent action of (9) nicotinamide/nicotinic acid-mononucleotide-adenylyltransferases (NMNAT1-3) and (10) NAD synthetase (NADSYN1) leads to the generation of NAD, which is then (11) phosphorylated to produce NADP. NAD can also derive directly from nicotinamide through the action of (12) nicotinamide phosphoribosyltransferase (NAMPT) and (13) nicotinamide/nicotinic acid-mononucleotide-adenylyltransferase (NMNAT1-3). Red frames: dietary precursors of NAD(P). Ala: alanine; Gln: glutamine; Glu: glutamate; PLP pyridoxal phosphate; PRPP: 5-phosphoribosyl-1- pyrophosphate.
Ijms 20 00974 g002
Figure 3. Schematic representation of distinct catabolic pathways. (1) NAD is hydrolyzed onto nicotinamide mononucleotide via the action of specific pyrophosphatases belonging to Nudix (nucleoside diphosphate linked to moiety X) family. (2) Nicotinamide mononucleotide is then dephosphorylated by Isn1 and Sdt1 cytosolic nucleotidases, which release the corresponding riboside cleaved to nicotinamide by a purine nucleoside phosphorylase (PNP) (3). Alternatively, NAD becomes a substrate of sirtuins (4), ADP-ribosyltransferases (ARTC) (5) and diphtheria toxin-like ADP-ribosyltransferases (ARTD) (6). Nicotinamide can be either re-converted to NAD by specific enzymes (7) (see also Figure 2) or methylated by nicotinamide-N-methyl transferase (NNMT) to N1-methylnicotinamide (8) that, in turn, (9) is oxidized to N1-methyl-4-pyridone-3-carboxamide (4-Py) and N1-methyl-2-pyridone-5-carboxamide (2-Py) by aldehyde oxidases. 2-OAADPr: O-acetyl-ADP ribose; NAMPT: nicotinamide phosphoribosyltransferase; NMNAT: nicotinamide/nicotinic acid-mononucleotide-adenylyltransferase; SAH: S-adenosylhomocysteine; SAM: S-adenosyl-methionine.
Figure 3. Schematic representation of distinct catabolic pathways. (1) NAD is hydrolyzed onto nicotinamide mononucleotide via the action of specific pyrophosphatases belonging to Nudix (nucleoside diphosphate linked to moiety X) family. (2) Nicotinamide mononucleotide is then dephosphorylated by Isn1 and Sdt1 cytosolic nucleotidases, which release the corresponding riboside cleaved to nicotinamide by a purine nucleoside phosphorylase (PNP) (3). Alternatively, NAD becomes a substrate of sirtuins (4), ADP-ribosyltransferases (ARTC) (5) and diphtheria toxin-like ADP-ribosyltransferases (ARTD) (6). Nicotinamide can be either re-converted to NAD by specific enzymes (7) (see also Figure 2) or methylated by nicotinamide-N-methyl transferase (NNMT) to N1-methylnicotinamide (8) that, in turn, (9) is oxidized to N1-methyl-4-pyridone-3-carboxamide (4-Py) and N1-methyl-2-pyridone-5-carboxamide (2-Py) by aldehyde oxidases. 2-OAADPr: O-acetyl-ADP ribose; NAMPT: nicotinamide phosphoribosyltransferase; NMNAT: nicotinamide/nicotinic acid-mononucleotide-adenylyltransferase; SAH: S-adenosylhomocysteine; SAM: S-adenosyl-methionine.
Ijms 20 00974 g003
Figure 4. Main molecular mechanisms underlying beneficial effects of niacin in the CNS under physio-pathological conditions. See text for further details. Akt: protein kinase B; Angpt: angiopoietin1; eNOS: endothelial nitric oxide synthase; MAPK: mitogen-activated protein kinase; PARP-1: poly(ADP-ribose) polymerase-1; SIRT1: sirtuin-1; TACE: tumor necrosis factor-alpha-converting enzyme.
Figure 4. Main molecular mechanisms underlying beneficial effects of niacin in the CNS under physio-pathological conditions. See text for further details. Akt: protein kinase B; Angpt: angiopoietin1; eNOS: endothelial nitric oxide synthase; MAPK: mitogen-activated protein kinase; PARP-1: poly(ADP-ribose) polymerase-1; SIRT1: sirtuin-1; TACE: tumor necrosis factor-alpha-converting enzyme.
Ijms 20 00974 g004
Table 1. Main findings on the role of niacin in neurodegeneration.
Table 1. Main findings on the role of niacin in neurodegeneration.
EffectorMain FindingsRef.
Alzheimer’s diseaseNiacinInverse association between AD and dietary niacin intakes [135]
NAD+High brain levels restore mitochondrial function and antagonize cognitive decline [138,139]
Nam/Nam mononucleotideProtect against Aβ-induced neurotoxicity via reduction of APP and PSEN-1 expression and ROS levels [140,141]
Nam ribosideReduces DNA damage, neuroinflammation and cell death of hippocampal neurons[142]
SIRT1Supports the non-amyloidogenic pathway of AD
Lessens AD neuroinflammation, oxidative stress and mitochondrial dysfunction
NMNAT1-3Protects against axon degeneration via reduction of nicotinamide mononucleotide levels and SIRT1 activation[132,133]
NMNAT2Activity downregulated prior to neurodegeneration; restoration of activity is neuroprotective against tauopathy
Low gene expression in AD patients
Parkinson’s diseaseNiacinIncreased intake enhances striatal dopamine synthesis and restores optimal NAD+/NADH ratio
High levels sequester transition metal ions
Low doses impact macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory) profile
NAD+Decreased levels in PD patients [148]
NADPHInhibits MPTP+-induced oxidative stress and glia-mediated neuroinflammation[152]
NNMTHigh levels in the cerebrospinal fluid and midbrain dopamine neurons of PD patients
High activity associated with low activity of mitochondrial complex 1; it counteracts the MPP+-dependent toxicity on mitochondrial complex 1 and activates neuronal autophagy
Induces neurite branching, synaptophysin expression and dopamine release
Huntington’s diseaseNADLow levels correlate with disease progression in Drosophila HD model [157]
NamProtects against the toxicity of polyQ proteins in Drosophila HD models
Restores BDNF protein levels, increases acetylated PGC-1α, improves motor deficits
Prevents motor abnormality via PARP-1-dependent inhibition of neuronal death and oxidative stress
SIRT1Rescues neurons from mutant huntingtin toxicity
Ameliorates pathological mechanisms underlying disease onset
AD: Alzheimer’s disease; APP: amyloid precursor protein; BDNF: brain-derived neurotrophic factor; HD: Huntington’s disease; MPTP+: N-methy-l-4-phenylpyridinium; Nam: nicotinamide; NMNAT: nicotinamide/nicotinic acid-mononucleotide-adenylyltransferases; NNMT: Nicotinamide N-Methyltransferase; PARP-1: poly(ADP-ribose) polymerase-1; PD: Parkinson’s disease; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1α; PSEN-1: presenilin-1; ROS: reactive oxygen species; SIRT1: sirtuin1.
Table 2. Main findings on the role of niacin in other neurological diseases.
Table 2. Main findings on the role of niacin in other neurological diseases.
EffectorMain FindingsRef.
Ischemic and traumatic injuriesNiacinDiminishes TBI-dependent behavioral deficits and improves functional recovery[175,176,177,178,179,180]
NamReduces neurologic deficits, hippocampal apoptosis, axonal injury and microglial activation in corpus callosum and oxidative stress; restores NAD(P) content; represses MAPK signaling and caspase 3 cleavage [181]
Nam mononucleotideAmeliorates hippocampal injury and improves neurological outcome, by decreasing poly-ADP-ribosylated proteins and NAD+ catabolism[182]
Nam/PARP-1 antagonistsPre-treatment improves ATP content and neuronal recovery during re-oxygenation [183]
Increases local cerebral blood flow; promotes angiogenesis via angpt/Tie2, Akt and eNOS pathways; promotes arteriogenesis via TACE and Notch signaling; ameliorates functional deficits[184,185]
Niacin plus seleniumAttenuate cortical cell injury, via an increase in Akt phosphorylation and expression of Nrf2; reduce oxidative stress.[186]
Nam plus progesteroneIncrease function recovery; reduce lesion cavitation and tissue loss; modulate expression of inflammatory and immune genes[187,188]
NAMPTDecreased activity exacerbates post-ischemic brain damage
Heterozygous gene deletion aggravates brain damage following photothrombosis-induced focal ischemia
Gene over-expression reduces infarct size
HeadachesNiacinRestores mitochondrial energy metabolism
Ameliorates blood flow and oxygenation in contracted skeletal muscle
Nicotinic acidDilates intracranial vessels and contracts extracranial vessels; increases skin biosynthesis of prostaglandin D2; rises plasma content of 9a,11b-prostaglandin F2 [194,195,196]
Psychiatric disordersNiacinLow dietary intakes in neuropsychiatric patients[197]
NamPositive correlation between vitamin levels and schizophrenia
Chronic supplementation effective in maintaining a bipolar type II patient stable and calm
Akt: protein kinase B; Angpt: angiopoietin1; eNOS: endothelial Nitric oxide synthase; MAPK: mitogen-activated protein kinase; Nam: nicotinamide; NAMPT: nicotinamide phosphoribosyltransferase; Nrf2: Nuclear factor (erythroid-derived 2)-like 2; PARP-1: poly(ADP-ribose) polymerase-1; TACE: tumor necrosis factor-alpha-converting enzyme; TBI: traumatic brain injury.

Share and Cite

MDPI and ACS Style

Gasperi, V.; Sibilano, M.; Savini, I.; Catani, M.V. Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications. Int. J. Mol. Sci. 2019, 20, 974.

AMA Style

Gasperi V, Sibilano M, Savini I, Catani MV. Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications. International Journal of Molecular Sciences. 2019; 20(4):974.

Chicago/Turabian Style

Gasperi, Valeria, Matteo Sibilano, Isabella Savini, and Maria Valeria Catani. 2019. "Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications" International Journal of Molecular Sciences 20, no. 4: 974.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop